Substituted tricyclic compound as PARP inhibitor and application thereof
By designing highly selective tricyclic compounds, the non-specific inhibition problem of existing PARP inhibitors on PARP1 and PARP2 is solved, and the efficient inhibition of PARP1 is achieved, reducing toxicity and side effects are reduced, and the selectivity of cancer treatment is enhanced. and security.
Patent Information
- Application Number
- CN202380026468.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-28
- Filing Date
- 2023-02-23
- Publication Date
- 2024-11-22
AI Technical Summary
Existing PARP inhibitors also inhibit PARP2 when inhibiting PARP1, resulting in side effects such as hair loss, diarrhea and hematotoxicity, limiting the use of combined with other targeted drugs.
Develop highly selective tricyclic compounds as PARP1 inhibitors, and through specific chemical structure design, it improves the affinity for PARP1 and reduces the inhibitory activity on PARP2.
It effectively reduces the toxicity related to mechanisms and is not related to mechanisms, improves the selectivity for cancer treatment, reduces the occurrence of side effects, and enhances the safety of combined use with other drugs.
Smart Images

Figure CN119013279A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to substituted tricyclic compounds as PARP inhibitors and their use. Background Art
[0002] Poly(ADP-ribose)polymerase (PARP) refers to a group of proteins whose function is to use NAD + They catalyze the addition of ADP-ribose to receptor proteins. This is one of the many ways in which proteins can be modified post-translationally. Therefore, they can also be called ADP-ribose transferases.
[0003] Based on the similarity of the amino acid sequence of the catalytic region of the protein, 17 different PARP enzymes have been found in human cells (Vyas et al., 2013 Nature Communication, 4: 3240 / 1-3240 / 13). These PARP enzymes either catalyze a single ADP-ribose modification of the receptor protein, or catalyze the transfer of multiple ADP-ribose to the receptor protein to form a multi-ADP-ribose, also known as poly (ADP-ribose) modification. PARP family members can be divided into two major subtypes based on whether the ADP-ribose transferred is single or multiple. The biological functions caused by the ADP-ribose modification of the receptor protein by the PARP enzyme cover a wide range, and many functions are still unclear.
[0004] PARP1 is the most abundant and most studied protein in the PARP family. PARP1 is a protein composed of 1014 amino acids (NCBI Accession P09874), with a molecular weight of approximately 116 kDa. Its structure includes DNA binding and catalytic regions. It is known that PARP1 is involved in multiple cellular functions and plays an important role in gene expansion, transcription, cell division, cell differentiation, apoptosis, and DNA damage response and repair mechanisms. When DNA damage occurs, PARP1 is activated. The base excision repair (BER) mechanism is a major mechanism for repairing single-strand DNA damage, and PARP1 is an important component of the BER mechanism. When damage occurs, PARP1 binds to the DNA single-strand damage (SSB) site and repairs DNA by participating in BER. Its activity is mainly reflected in the ADP-ribose modification of histones and nucleoproteins and its own ADP-ribose modification. In addition to the BER repair mechanism for single-strand damage, cells also have two important repair mechanisms for repairing double-strand damage: homologous recombination (HR) and non-homologous recombination end joining (NHEJ). The results showed that cancer cells with defects in the homologous recombination repair mechanism are sensitive to PARP1 inhibitors, that is, homologous recombination defects and PARP1 inhibition form a pair of synthetic lethality. This discovery has been verified clinically, and multiple PARP inhibitors have been approved for marketing for the treatment of ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer with DNA damage repair defects such as BRCA1 / 2 mutations.
[0005] PARP2 is a protein composed of 559 amino acids (NCBI Accession NP_005475), with a molecular weight of approximately 62 kDa. Its structure includes DNA binding and catalytic regions (Ame et al., 1999 J Biol Chem 274: 17860-17868). The catalytic region of PARP2 is highly similar to that of PARP1. Studies have shown that PARP2 has similar functions to PARP1 and participates in the repair of DNA damage by the BER mechanism (Schreiber et al., 2002 J Biol Chem 277: 23028-23036). Currently available PARP inhibitors, including Olaparib, Niraparib, Talazoparib and Rucaparib, have similar inhibitory activity against PARP2 in addition to inhibiting PARP1. From the results of clinical trials, these PARP inhibitors that have been marketed have similar efficacy, but their toxicity is quite different. For example, Talazoparib has a side effect of hair loss similar to that of chemotherapy drugs. A recent study comparing the selectivity of multiple PARP inhibitors showed that in addition to inhibiting PARP1 and PARP2, Talazoparib also has a relatively high affinity for two other members of the PARP family, TNKS1 (Tankyrase 1) and TNKS2 (Tankyrase 2) (Ryan et al., 2021 J Biol Chem 296:100251 / 1-100251 / 13). The amino acid sequences of TNKS1 and TNKS2 are highly similar, with 83% of the amino acid sequences in the overall sequence of the two being identical, and the catalytic region being 89% identical. In addition to playing a role in DNA repair, TNKS also plays a role in maintaining telomere structure and the Wnt / -catenin signaling pathway. Inhibition of these targets other than PARP1 may be the cause of extra-mechanistic toxicity, such as hair loss and diarrhea. In addition, inhibition of PARP2 activity may also lead to hematologic toxicity (Farrés et al., 2013 Blood 122:44-54; Farrés et al., 2015 Cell Death and Differentiation 22:1144-1157). These toxicities may limit the combined use of PARP inhibitors and other targeted drugs.
[0006] Therefore, the development of highly selective PARP1 inhibitors may reduce both mechanism-related and mechanism-irrelevant toxicities.
[0007] A variety of selective PARP1 inhibitors have been disclosed, such as WO2011006803, WO2013014038, WO2021013735, WO2021260092, CN115232129A, WO2022225934, WO2022222921, WO2022222964, WO2022222965, WO2022222966, WO202228387, WO2022247816, WO2022223025 and WO2022222995. Summary of the invention
[0008] The present invention provides compounds with structures as shown in Formula I (including Formula II, III, IV, V, VI, VII, VIII and IX), which can be used as PARP inhibitors. In particular, the compounds of the present invention are selective PARP1 inhibitors relative to PARP2.
[0009] The present invention also provides a pharmaceutical composition comprising an effective amount of a compound of Formula I (including Formulas II, III, IV, V, VI, VII, VIII and IX) for treating cancer.
[0010] In one embodiment, the pharmaceutical composition may further contain one or more pharmaceutically acceptable carriers or excipients or diluents for treating cancer.
[0011] In one embodiment, the pharmaceutical composition may further contain at least one known anticancer drug or a pharmaceutically acceptable salt of the anticancer drug for treating cancer.
[0012] The present invention also relates to a process for preparing novel compounds of formula I (including formula II, III, IV, V, VI, VII, VIII and IX). DETAILED DESCRIPTION
[0013] It should be understood that the features of the various embodiments described herein can be arbitrarily combined to form the technical solutions of this invention; the definition of each group herein is applicable to any embodiment described herein, for example, the definition of substituents of alkyl groups herein is applicable to any embodiment described herein, unless the embodiment has clearly defined substituents of alkyl groups.
[0014] As used herein, "hydrogen" or "H" are used interchangeably and include the isotopes deuterium (D) and tritium (T).
[0015] The heteroatoms described herein include oxygen (O), sulfur (S) and nitrogen (N).
[0016] As used herein, "alkyl" refers to an alkyl group itself or a straight or branched chain group of up to ten carbon atoms. Useful alkyl groups include straight or branched chain C 1-10Alkyl, preferably C 1-6 In certain embodiments, the alkyl group is C 1-4 In some embodiments, the alkyl group is C 1-3 In some embodiments, the alkyl group is a deuterated C 1-3 Alkyl. Typical C 1-10 Alkyl groups include optionally substituted methyl, trideuterated methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl (eg, 3-pentyl), hexyl, and octyl.
[0017] As used herein, "alkenyl" refers to a straight or branched chain containing 2 to 10 carbon atoms, unless the carbon chain length is otherwise limited, wherein at least two carbon atoms in the chain contain a double bond; preferably C 2-6 Typical alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl and 2-butenyl.
[0018] As used herein, "alkynyl" refers to a straight or branched chain containing 2 to 10 carbon atoms, unless the carbon chain length is otherwise limited, wherein at least two carbon atoms in the chain contain a triple bond; preferably C 2-6 Typical alkynyl groups include ethynyl, 1-propynyl, 1-methyl-2-propynyl, 2-propynyl, 1-butynyl and 2-butynyl.
[0019] Useful alkoxy groups include those represented by the above C 1-10 Alkyl, preferably C 1-6 Alkyl or C 1-4 Alkyl or C 1-3 Alkyl substituted oxy, such as methoxy, ethoxy, etc. The alkyl in the alkoxy group may be optionally substituted. The substituents of the alkoxy group include, but are not limited to, halogen, morpholinyl, amino (including alkylamino and dialkylamino) and carboxyl (including ester groups thereof).
[0020] Useful amino and optionally substituted amino groups are -NR'R", wherein R' and R" are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably, R' and R" are each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 3-6 membered heterocyclyl or optionally substituted 5 membered heteroaryl; or R′ and R″ together with the N to which they are attached form an optionally substituted 4- to 7-membered cyclic amino group, the cyclic amino group optionally containing one or more (such as 2, 3) additional heteroatoms selected from O, N and S. Preferably, R′ and R″ are each independently selected from hydrogen, optionally substituted C 1-4Alkyl, optionally substituted C 3-6 Cycloalkyl and optionally substituted 3- to 6-membered heterocyclic groups.
[0021] As used herein, "oxo" refers to =0.
[0022] As used herein, "aryl" refers to an aromatic group, either by itself or as part of another group, containing 6 to 14 carbon atoms, a monocyclic, bicyclic or tricyclic aromatic group. The aryl group may be substituted with one or more substituents described herein.
[0023] Useful aromatic groups include C 6-14 Aryl, preferably C 6-10 Aryl. Typical C 6-14 Aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylene and fluorenyl.
[0024] As used herein, "carbocyclic group" includes cycloalkyl and partially saturated carbocyclic groups. Useful cycloalkyl groups are C 3-8 Cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Useful partially saturated carbocyclic groups include cycloalkenyl, such as C 3-8 Cycloalkenyl groups, such as cyclopentenyl, cycloheptenyl, and cyclooctenyl.Carbocyclic groups may be substituted with one or more substituents as described herein.
[0025] Useful halogens or halogen groups include fluorine, chlorine, bromine and iodine.
[0026] Useful acylamino groups (amido groups) are any C 1-6 Acyl (alkanoyl) groups such as acetylamino, acetylamino, propionylamino, butyrylamino, pentanoylamino and hexanoylamino, and aryl-substituted C 1-6 Acylamino, for example benzylamino.
[0027] Useful acyl groups include C 1-6 Acyl, such as acetyl. The acyl group may be optionally substituted by a group selected from halogen, amino and aryl, wherein amino and aryl are optionally substituted. When substituted by halogen, the number of halogen substituents may be in the range of 1-5. Examples of acyl substituted by halogen include chloroacetyl and pentafluorobenzoyl, etc. When substituted by amino, the amino group may be substituted by 1 or 2 substituents described herein. In some embodiments, aminoacyl is -C(O)-NR′R″, wherein R′ and R″ are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably, R' and R" are each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6Cycloalkyl and optionally substituted 3-6 membered heterocyclyl.
[0028] As used herein, "heterocyclic group" refers to a saturated or partially saturated 3-7-membered monocyclic group, a 7-10-membered bicyclic group, a spirocyclic group or a bridged cyclic group, which is composed of carbon atoms and 1-4 heteroatoms selected from O, N, and S, wherein the heteroatoms nitrogen and sulfur can be oxidized at will, and the nitrogen can also be quaternized at will. The heterocyclic group also includes a fused heterocyclic ring formed by condensing any heterocyclic ring defined above with a benzene ring in the bicyclic system. If the resulting compound is stable, the carbon atoms or nitrogen atoms of the heterocyclic ring can be substituted. The heterocyclic group can be substituted by one or more substituents described herein.
[0029] Useful saturated or partially saturated heterocyclic groups include tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, 1,4-diazepanyl, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetrahydroisoquinolinyl, tetronoyl and tetramoyl, which groups may be substituted with one or more substituents as described herein.
[0030] As used herein, "heteroaryl" refers to a group containing 5-14, preferably 5-10 ring atoms, and having 6, 10 or 14 π electrons shared in the ring system. The ring atoms contained in the heteroaryl group are carbon atoms and 1-3 heteroatoms selected from oxygen, nitrogen and sulfur. The heteroaryl group may be substituted with one or more substituents described herein.
[0031] Useful heteroaryl groups include thienyl (phenylthio), benzo[d]isothiazol-3-yl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furanyl, pyranyl, isobenzofuranyl, chromenyl, xanthrenyl, phenoxanthiinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl (including but not limited to 2-pyridyl, 3-pyridyl and 4-pyridyl), pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, β-carbolinyl, phenanthridinyl, azathiophene, pyridinyl, perylene diazine (iso)phenyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, tetrahydropyridopyrimidinyl, tetrahydro five-membered [c] pyrazol-3-yl, benzisoxazolyl such as 1,2-benzisoxazol-3-yl, benzimidazolyl, 2-hydroxyindolyl, thiadiazo, 2-oxobenzimidazolyl, imidazopyridazinyl, imidazopyridinyl, triazolopyridazinyl, tetrahydropyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyridinyl, pyrrolopyrazinyl, triazolopyrazinyl, thienoquinolyl, furanoquinolyl, thiazoquinolyl, pyrazoloquinolyl, pyrroloquinolyl, imidazoquinolyl, oxazoloquinolyl and the like. When the heteroaryl group contains a nitrogen atom in a ring, such nitrogen atom may be in the form of an N-oxide, for example, pyridinyl N-oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.
[0032] As used herein, unless otherwise indicated, when substituted, the alkyl, cycloalkyl, heterocycloalkyl, alkoxy, heterocycloalkoxy, alkenyl, heterocycloalkenyl, alkynyl, amino, amido, acyloxy, carboxyl, hydroxyl, thiol, alkylthio, sulfonyl, sulfinyl, aminoacyl, silanyl, phosphono, phosphono, carbocyclyl, heterocyclyl, aryl or heteroaryl groups described in any embodiment herein may be substituted with one or more (e.g., 1, 2, 3, 4, 5 or 6) substituents selected from the group consisting of halogen, hydroxyl, carboxyl, amino, nitro, cyano, C 1-6 Acylamino, C 1-6 Acyloxy, C 1-6 Alkoxy, aryloxy, alkylthio, C 1-6 Alkyl, C 1-6 Acyl, C 6-10 Aryl, C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, heterocyclic or heteroaryl, methylenedioxy, ureido, thiol, azido, carbonyl, alkylsulfonyl, sulfamoyl, dialkylsulfamoyl and alkylsulfinyl, etc. The substituents themselves are optionally substituted. More preferred substituents include, but are not limited to, halogen, hydroxyl, carboxyl, amino, C1-6 Acylamino, C 1-6 Acyloxy, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Acyl and alkanesulfonyl groups.
[0033] It should be understood that in each embodiment herein, when the substituent is a heterocyclic group, an aryl group or a heteroaryl group, the number of the heterocyclic group, the aryl group or the heteroaryl group substituent is usually one.
[0034] Specifically, the present invention provides a compound as shown in the following formula I, its stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts, or mixtures thereof, or prodrugs thereof: wherein A1, A2 and A3 are each independently selected from N and CR1; The Z ring is as follows , wherein the Z ring is an optionally substituted 5-membered heteroaryl, an optionally substituted 5-membered carbocyclyl or an optionally substituted 5-membered heterocyclyl, * represents the position where the Z ring is connected to the rest of the compound, and the dotted line represents the optional presence of an unsaturated bond, wherein when the Z ring is an optionally substituted 5-membered heteroaryl, Z1, Z2 and Z3 are each independently CR2, NR3, O, N or S, Z4 and Z5 are each independently C or N, and Z4 and Z5 are not N at the same time; when the Z ring is an optionally substituted 5-membered carbocyclyl or an optionally substituted 5-membered heterocyclyl, Z1, Z2 and Z3 are each independently CR2R2', CR2, NR3, O or S, and Z4 and Z5 are each independently C, CH or N; And it satisfies: when Z5 is N, at least one of Z1, Z2 and Z3 is N, or when Z5 is N and Z1-Z3 are all CR2 or CR2R2', A1 is CR1; L is selected from a bond and an alkylene group optionally substituted by R4 and / or R5; Cy is selected from optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl; R1 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy and optionally substituted carbocyclyl; R2 and R2' are each independently selected from hydrogen, hydroxy, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl; R4 and R5 are each independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted alkenyl and optionally substituted alkynyl; or R4 and R5 form a ring with the attached C.
[0035] In Formula I and various structural formulas of the present invention, unless otherwise specified, each alkyl group may be independently C 1-6 Alkyl, preferably C 1-4 Alkyl; each alkylene group may be C 1-6 Alkylene, preferably C 1-3 Alkylene; each alkenyl group can be independently C 2-6 Alkenyl, preferably C 2-4 Alkenyl; each alkynyl group can be independently C 2-6 Alkynyl, preferably C 2-4 Alkynyl; each alkoxy group can be independently C 1-6 Alkoxy, preferably C 1-4 Preferably, when the alkyl, alkenyl, alkynyl, and alkoxy groups are substituted, the substituents may be selected from cyano, hydroxyl, nitro, amino (-NR'R"), aryl, heterocyclic, heteroaryl, halogen, and carboxyl groups, and the number of substituents may be 1-5, and R' and R" are preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Cycloalkyl and optionally substituted 3-6 membered heterocyclyl. For example, the substituted alkyl itself or the substituted alkyl as a substituent of other groups can be hydroxyalkyl, dihydroxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heterocyclylalkyl, aralkyl, heteroarylalkyl and haloalkyl. It should be understood that when the substituent is aryl, heteroaryl, heterocyclyl, cyano, nitro and carboxyl, the number of substituents is usually 1; when the substituent is, for example, halogen, the number of substituents can be up to 5 halogen groups depending on the carbon chain length of the alkyl, alkenyl, alkynyl and alkoxy groups; exemplary substituents of this type are trifluoromethyl and pentafluoroethyl.
[0036] In Formula I and various structural formulas of the present invention, unless otherwise specified, the number of carbon atoms in each carbocyclic group is preferably 3-8. 3-8 The substituent on the carbocyclic group is preferably C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, halogen, hydroxyl, carboxyl, amino (-NR'R"), aryl, heterocyclic, heteroaryl, halogen and carboxyl, etc., the number of substituents can be 1-5, R' and R" are preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Cycloalkyl and optionally substituted 3-6 membered heterocyclyl. It should be understood that when the substituent is aryl, heteroaryl, heterocyclyl, cyano, nitro, and carboxyl, the number of substituents is generally 1; when the substituent is, for example, halogen, the number of substituents can be up to 5 halogen groups.
[0037] In the formula I and various structural formulas of the present invention, unless otherwise specified, aryl generally refers to C 6-14 Aryl and heteroaryl usually refer to 5-10 membered heteroaryl groups, and heterocyclyl usually refers to 4-10 membered heterocyclyl groups. The number of substituents on each aryl, heteroaryl and heterocyclyl group may be 1-5, each of which may be independently selected from C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 alkoxy, halogen, hydroxy, carboxyl, amino (-NR'R"), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic group, halogen, acylamino, aminoacyl (-C(O)-NR'R") and carboxyl, wherein R' and R" are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably, R' and R" are each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 The above-mentioned optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocyclic group may be optionally substituted by 1-5 groups selected from C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, halogen, hydroxy, carboxyl, amino (-NR'R"), aminoacyl (-C(O)-NR'R"), halogen and carboxyl substituents, wherein R' and R" are preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Cycloalkyl or optionally substituted 3-6 membered heterocyclyl. It should be understood that when the substituent is aryl, heteroaryl, heterocyclyl, cyano, nitro or carboxyl, the number of substituents is generally 1; when the substituent is, for example, halogen, the number of substituents can be up to 5 halogen groups.
[0038] In some embodiments, the present invention does not include compounds having the following structural formula or stereoisomers, solvates or pharmaceutically acceptable salts thereof: Wherein, Y is N, CH or CF; A 1 is CH2, CF2, CHF, CHCH3 or C(CH3)2; B 1 is CH2, CF2, CHF, CHCH3 or C(CH3)2; C 1 is O or S; and Wherein, Y is N, CH or CF; A 4 It is H, C 1-6 Alkyl or halogenated C1-6 Alkyl; B 4 It is H, C 1-6 Alkyl or halogenated C 1-6 Alkyl; C 4 is O or S; and Wherein, Y is N, CH or CF; A 5 O or S; B 5 It is H, C 1-6 Alkyl or halogenated C 1-6 Alkyl; C 5 It is H, C 1-6 Alkyl or halogenated C 1-6 Alkyl; and Wherein, Y is N, CH or CF; A 6 It is H, C 1-6 Alkyl or halogenated C 1-6 Alkyl; B 6 is O or S; and Wherein, Y is N, CH or CF; A 7 O or S; B 7 is CH2, CF2, CHF, CHCH3 or C(CH3)2; C 7 is CH2, CF2, CHF, CHCH3 or C(CH3)2; and In the formula, R A Selected from C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 Alkyl or C 1-3 Alkoxy; R B and R C are selected from H, halogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 Alkyl or C 1-3 Alkoxy; Y is selected from CH or N.
[0039] In some embodiments, the compounds of the present invention do not include the following compounds:
[0040] In some embodiments, the compounds of the present invention do not include the following compounds:
[0041] In one or more embodiments of the compound of formula I, the preferred compound is a compound represented by formula Ia, Ib, Ic or Id, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof: Wherein, A1, A2, A3, Z ring (including Z1, Z2 and Z3), L and Cy are as described in Formula I.
[0042] In one or more embodiments of Formula Ia: A1, A2 and A3 are each independently selected from N and CR1; The Z ring is as follows The optionally substituted 5-membered heteroaryl shown, * represents the position where the Z ring is connected to the rest of the compound, wherein Z1, Z2 and Z3 are each independently CR2, NR3, O, N or S; L is selected from a bond and an alkylene group optionally substituted by R4 and / or R5; Cy is selected from optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl; R1 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy and optionally substituted carbocyclyl; R2 is selected from the group consisting of hydrogen, hydroxy, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl; R4 and R5 are each independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted alkenyl and optionally substituted alkynyl; or R4 and R5 form a ring with the attached C.
[0043] In one or more embodiments of compounds of Formula I (including Formulas Ia, Ib, Ic, and Id), the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen and optionally substituted C 1-3 Alkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C3-6 Cycloalkyl, preferably hydrogen, halogen and optionally substituted C 1-3 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen or optionally substituted C 1-3 alkyl.
[0044] In one or more embodiments of the compound of formula Ia, the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, optionally substituted C 1-6 Alkyl and optionally substituted C 1-3 Alkoxy, preferably hydrogen, halogen and optionally substituted C 1-3 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen or optionally substituted C 1-3 alkyl.
[0045] In one or more embodiments of the compounds of Formula Ib and Ic, the Z ring is selected from the following groups: wherein R2 and R2′ are as described in any embodiment herein; preferably, in these embodiments, at least one of A2 and A3 is CR1, and R1 is halogen; in some embodiments, A2 and A3 are both CR1, and at least one R1 is halogen. In some embodiments, A3 is CR1, and R1 is halogen. In some embodiments, A1 is CR1, and A2 and A3 are both CH; or A1 is CH, A2 is CR1, and A3 is CH; or A1 and A2 are both CH, A3 is CR1, and R1 is halogen.
[0046] Herein, the substituents on the Z ring may be 1-2 selected from hydroxyl, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, hydroxy substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkoxy and amino (-NR'R") substituents, wherein R' and R" are preferably each independently H or C 1-4 In some embodiments, the substituents on the Z ring may be 1-2 selected from halogen, C 1-4 Alkyl and C 3-6 Substituents on a cycloalkyl group.
[0047] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), A1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 In some embodiments, at least one of A1 and A3 is CR1, and R1 is a halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is a halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is a halogen. In some embodiments, A3 is CR1, and R1 is a halogen. In one or more embodiments, A1, A2, and A3 are all CR1, and R1 is each independently hydrogen, halogen, or C 1-3 In some embodiments, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0048] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), when the Z ring is not When A1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 Preferably, at least one of A1 and A3 is CR1, and R1 is a halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is a halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is a halogen. In some embodiments, A3 is CR1, and R1 is a halogen. In one or more embodiments, A1, A2, and A3 are all CR1, and R1 is each independently hydrogen, halogen, or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0049] In one or more embodiments of the compound of Formula Ib, when the Z ring is When A1 is CR1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 Preferably, A3 is CR1, and R1 is halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is halogen. In one or more embodiments, A1, A2 and A3 are all CR1, and R1 is independently hydrogen, halogen or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0050] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), R1 is hydrogen, halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Preferably, when R1 is substituted, the number of substituents may be 1-5, which may be selected from halogen, hydroxyl and amino (-NR'R"), etc., wherein R' and R" are preferably each independently H, optionally substituted C 1-4 Alkyl or optionally substituted C 3-6 Preferably, R1 is hydrogen, halogen or C 1-3 alkyl.
[0051] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib and Ic), R2 is hydrogen, halogen, cyano, C 1-3 Alkyl or C 3-6 Cycloalkyl.
[0052] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), R3 is hydrogen or C 1-3 alkyl.
[0053] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), R2′ is hydrogen, halogen, cyano, C 1-3 Alkyl or C 3-6 Cycloalkyl.
[0054] In one or more embodiments of the compound of Formula Id, R2 and R2' are both hydrogen.
[0055] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), R4 and R5 are preferably each independently halogen or C 1-3 In some embodiments, R4 and R5 form a 3-6 membered cycloalkyl with the attached C.
[0056] In one or more embodiments of the compounds of Formula I (including Formulas Ia, Ib, Ic and Id), L is optionally substituted with 1-2 C 1-3 Alkyl substituted alkylene, more preferably optionally substituted with 1-2 C 1-3 Alkyl substituted C 1-3 Alkylene, preferably optionally substituted with 1-2 C 1-3 Alkyl substituted methylene.
[0057] In one or more embodiments of the compound of Formula I (including Formulas Ia, Ib, Ic and Id), L is unsubstituted alkylene, more preferably unsubstituted C 1-3 The alkylene group is preferably a methylene group.
[0058] In one or more embodiments of the compound of formula I (including formulas Ia, Ib, Ic and Id), the aryl group is preferably a phenyl group; the heteroaryl group is a 5-10 membered heteroaryl group containing 1 or 2 nitrogen atoms, including but not limited to pyridyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrimidinyl, pyridazinyl and indolizinyl; the carbocyclic group is preferably C 3-8 Cycloalkyl and C 3-8 Cycloalkenyl; the heterocyclic group is preferably a 4-10 membered heterocyclic group containing O, S and / or N, including but not limited to azetidinyl, oxetanyl, pyrrolidinyl, piperazinyl, piperidinyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydroisoquinolyl, tetrahydropyranyl and morpholinyl, etc.
[0059] In one or more embodiments of the compound of formula I (including formula Ia, Ib, Ic and Id), Cy is an optionally substituted 5-7 membered nitrogen-containing heterocyclic group. Preferably, the 5-7 membered nitrogen-containing heterocyclic group is covalently linked to L via its ring nitrogen atom. Further preferably, Cy is an optionally substituted piperazinyl, piperidinyl, dihydropyridinyl or pyrrolidinyl. Preferably, the substituents on Cy of the compound of formula I (including formula Ia, Ib, Ic and Id) are selected from: halogen, optionally substituted C 1-4 Alkyl, optionally substituted C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 alkoxy, cyano, hydroxy, amino (-NR'R"), optionally substituted 6-14 membered aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 4-10 membered heterocyclyl, and optionally substituted C 3-8 Cycloalkyl; wherein the 6-14 membered aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclic group and C 3-8 Each cycloalkyl group may be independently substituted by 1 to 5 groups selected from halogen, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4Alkoxy, C 3-6 substituted with cycloalkyl, amino (-NR'R"), aminoacyl (-C(O)-NR'R"), and carboxyl; wherein R' and R" are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-8 cycloalkyl or an optionally substituted 3-6 membered heterocyclyl; in a preferred embodiment, the 6-14 membered aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl and C 3-8 The substituents on the cycloalkyl group include at least aminoacyl (-C(O)-NR'R"), and optionally further include halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6 In a preferred embodiment, Cy is substituted by an optionally substituted 5-10 membered heteroaryl, preferably by an optionally substituted 5-10 membered nitrogen-containing heteroaryl (such as pyridyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrimidinyl, etc.), preferably, the 5-10 membered heteroaryl or 5-10 membered nitrogen-containing heteroaryl is at least substituted by the aminoacyl (-C(O)-NR'R"), and optionally further substituted by halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6 Preferably, the aminoacyl group (-C(O)-NR'R") is located at the para position. In a particularly preferred embodiment, Cy is piperazinyl substituted by an optionally substituted pyridyl group, piperidinyl substituted by an optionally substituted pyridyl group, or dihydropyridinyl substituted by an optionally substituted pyridyl group, and the pyridyl group is at least substituted by the aminoacyl group (-C(O)-NR'R"). Preferably, herein, when R' and R" are substituted, the number of substituents may be 1-5, which may be selected from halogen, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 In some embodiments, Cy is substituted by the amino group (-NR'R"), wherein one substituent of the amino group is an optionally substituted 5-10 membered nitrogen-containing heteroaryl group. Preferably, Cy is a pyrrolidinyl group substituted by an optionally substituted pyridinylamino group.
[0060] In one or more embodiments of the compounds of formula I or Ia of the present invention, ring Z is:
[0061] wherein * indicates the position where the Z ring is connected to the rest of the compound; A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; L and Cy are as described in any embodiment herein. In one or more embodiments of the compound of formula I or Ic of the present invention, ring Z is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 and at least one of R2 and R2' is a non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy is preferably halogen, more preferably F; L and Cy are as described in any embodiment herein.
[0062] In one or more embodiments of the compounds of formula I or Ic of the present invention, ring Z is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C1-3 Alkoxy is preferably halogen, more preferably F; L and Cy are as described in any embodiment herein.
[0063] One group of preferred compounds of formula I of the present invention is represented by compounds represented by formula II (including formula IIa, IIb, IIc and IId) or stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts thereof, or mixtures thereof, or prodrugs thereof: wherein A1, A2, A3, Z1, Z2 and Z3 are as described in any one of the embodiments of Formulas I, Ia, Ib, Ic and Id; R6 is selected from optionally substituted aryl and optionally substituted heteroaryl.
[0064] In one or more embodiments of the compound represented by Formula II (including Formula IIa, IIb, IIc and IId), the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen and optionally substituted C 1-3 Alkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen and optionally substituted C 1-3 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 alkyl.
[0065] In one or more embodiments of the compound of formula IIa, the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, optionally substituted C 1-6 Alkyl and optionally substituted C 1-3 Alkoxy, preferably hydrogen, halogen and optionally substituted C 1-3 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 alkyl.
[0066] In one or more embodiments of the compounds of formula IIb and IIc, the Z ring is selected from the following groups: wherein R2 and R2' are as described in any embodiment herein; preferably, in these embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one of R1 is halogen. In some embodiments, A3 is CR1, and R1 is halogen. In some embodiments, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, and A3 is CH; or A1 and A2 are both CH, A3 is CR1, and R1 is halogen.
[0067] In one or more embodiments of the compound of formula II (including formula IIa, IIb, IIc and IId), A1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 In some embodiments, at least one of A1 and A3 is CR1, and R1 is a halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is a halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is a halogen. In some embodiments, A3 is CR1, and R1 is a halogen. In one or more embodiments, A1, A2, and A3 are all CR1, and R1 is each independently hydrogen, halogen, or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0068] In one or more embodiments of the compound of Formula II (including Formula IIa, IIb, IIc and IId), when the Z ring is not When A1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3Preferably, at least one of A1 and A3 is CR1, and R1 is a halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is a halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is a halogen. In some embodiments, A3 is CR1, and R1 is a halogen. In one or more embodiments, A1, A2, and A3 are all CR1, and R1 is each independently hydrogen, halogen, or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0069] In one or more embodiments of the compound of Formula IIb, when the Z ring is When A1 is CR1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 Preferably, A3 is CR1, and R1 is halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is halogen. In one or more embodiments, A1, A2 and A3 are all CR1, and R1 is independently hydrogen, halogen or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0070] In one or more embodiments of the compound represented by Formula II (including Formula IIa, IIb, IIc and IId), R6 is an optionally substituted 6-14 membered aryl or an optionally substituted 5-10 membered heteroaryl, wherein the 6-14 membered aryl and the 5-10 membered heteroaryl are each independently substituted by 1-5 groups selected from halogen, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, C 3-6 Cycloalkyl, amino (-NR'R"), aminoacyl (-C(O)-NR'R"), carboxyl, and optionally 1-3 C 1-4 substituted with a substituent of an alkyl-substituted heteroaryl (such as a 5-10-membered nitrogen-containing heteroaryl, especially a 5-membered or 6-membered nitrogen-containing heteroaryl), wherein R′ and R″ are each independently hydrogen, an optionally substituted C1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Cycloalkyl or an optionally substituted 3-6 membered heterocyclic group; in a preferred embodiment, the substituents of R6 include at least aminoacyl (-C(O)-NR'R"), and optionally further include halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6 In a preferred embodiment, R6 is an optionally substituted 5-10 membered heteroaryl, preferably an optionally substituted 5-10 membered nitrogen-containing heteroaryl, preferably, the 5-10 membered heteroaryl or 5-10 membered nitrogen-containing heteroaryl is at least substituted by the aminoacyl (-C(O)-NR'R"), and optionally further substituted by halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6 Preferably, when R' and R" are substituted, the number of substituents may be 1-5, which may be selected from halogen, hydroxyl and amino.
[0071] Preferably, R6 is an optionally substituted phenyl, pyridyl, pyrimidyl, pyrazinyl or pyridazinyl. Preferably, when R6 is substituted, the number of substituents may be 1-5, and may be selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, C 3-6 More preferably, R6 is substituted by at least one aminoacyl group, preferably, the aminoacyl group is in the para position of R6. Preferably, the aminoacyl group is -C(O)-NR′R″, wherein R′ and R″ are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Preferably, when the R' and R" are substituted, the number of substituents may be 1-5, which may be selected from halogen, hydroxyl, oxy and amino. Preferably, the optionally substituted alkyl and optionally substituted alkoxy may be optionally substituted by 1-5 substituents selected from halogen, hydroxyl, oxy and amino. In a preferred embodiment, the substituents on R6 include at least aminoacyl (-C(O)-NR'R"), and optionally include halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6Any one or both of the cycloalkyl groups, further preferably, the aminoacyl group (-C(O)-NR'R") is located at the para position.
[0072] In one or more embodiments of the compound represented by Formula II (including Formula IIa, IIb, IIc and IId), R6 is preferably the following group: wherein B1, B2, B3 and B4 are each independently selected from N and CR7; R7 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted carbocyclyl, optionally substituted alkenyl and optionally substituted alkynyl; wherein R′ and R″ are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 cycloalkyl or optionally substituted 3-6 membered heterocyclic group; * indicates the position where the group is connected to the rest of the compound. Preferably, the group containing B1, B2, B3 and B4 is phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl. Preferably, R7 is H, halogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkyl or C 3-6 Preferably, B3 is N, B4 is CR7, B1 and B2 are CH, wherein R7 is H, halogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkyl or C 3-6 Preferably, when R' and R" are substituted, the number of substituents may be 1-5, and may be selected from halogen, hydroxyl and amino. Preferably, R' is hydrogen, R" is hydrogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl, hydroxy substituted C 1-3 Alkyl or C 3-6 Heterocyclic group.
[0073] Preferably, herein, the optionally substituted alkyl, optionally substituted alkoxy, optionally substituted carbocyclyl, optionally substituted alkenyl and optionally substituted alkynyl described by R7 may each be optionally substituted by 1-5 substituents selected from halogen, hydroxyl and amino.
[0074] In one or more embodiments of the compounds of formula IIa of the present invention, the Z ring is: wherein * indicates the position where the Z ring is connected to the rest of the compound; A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; R6 is as described in any embodiment herein.
[0075] In one or more embodiments of the compound of formula IIc of the present invention, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 and at least one of R2 and R2' is a non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; R6 is as described in any embodiment herein.
[0076] In one or more embodiments of the compound of formula IIc of the present invention, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; R6 is as described in any embodiment herein.
[0077] One group of preferred compounds of formula I of the present invention is represented by compounds represented by formula III (including formula IIIa, IIIb, IIIc and IIId) or their stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts, or mixtures thereof, or prodrugs thereof: wherein Z1, Z2, Z3, A1, A2 and A3 are as described in any of the preceding embodiments; B1, B2, B3 and B4 are each independently selected from N and CR7; R7 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted carbocyclyl, optionally substituted alkenyl, and optionally substituted alkynyl; R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
[0078] In one or more embodiments of the compound represented by Formula III (including Formula IIIa, IIIb, IIIc and IIId), the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 alkyl.
[0079] In one or more embodiments of the compound of formula IIIa, the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 alkyl.
[0080] In one or more embodiments of the compounds of formula IIIb and IIIc, the Z ring is selected from the following groups: wherein R2 and R2' are as described in any embodiment herein; preferably, in these embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one of R1 is halogen. In some embodiments, A3 is CR1, and R1 is halogen. In some embodiments, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, and A3 is CH; or A1 and A2 are both CH, A3 is CR1, and R1 is halogen.
[0081] In one or more embodiments of the compound of formula III (including formula IIIa, IIIb, IIIc and IIId), A1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 In some embodiments, at least one of A1 and A3 is CR1, and R1 is a halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is a halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is a halogen. In some embodiments, A3 is CR1, and R1 is a halogen. In one or more embodiments, A1, A2, and A3 are all CR1, and R1 is each independently hydrogen, halogen, or C 1-3Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0082] In one or more embodiments of the compound of formula III (including formula IIIa, IIIb, IIIc and IIId), when the Z ring is not When A1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 Preferably, at least one of A1 and A3 is CR1, and R1 is a halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is a halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is a halogen. In some embodiments, A3 is CR1, and R1 is a halogen. In one or more embodiments, A1, A2, and A3 are all CR1, and R1 is each independently hydrogen, halogen, or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0083] In one or more embodiments of the compound of formula IIIb, when the Z ring is When A1 is CR1, A2 and A3 are each independently selected from N and CR1, wherein R1 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, more preferably, R1 is hydrogen, halogen or C 1-3 Preferably, A3 is CR1, and R1 is halogen, such as fluorine. In some embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one R1 is halogen. In one or more embodiments, A1, A2 and A3 are all CR1, and R1 is independently hydrogen, halogen or C 1-3 Preferably, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, A3 is CH; or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen or C 1-3 alkyl.
[0084] In one or more embodiments of the compound represented by Formula III (including Formula IIIa, IIIb, IIIc and IIId), B1, B2, B3 and B4 are each independently selected from N and CR7, wherein R7 is preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, more preferably R7 is hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 In a preferred embodiment, B1 and B2 are both CH, B3 is N, B4 is CR7, wherein R7 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, more preferably R7 is hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl.
[0085] In one or more embodiments of the compound represented by Formula III (including Formula IIIa, IIIb, IIIc and IIId), R′ and R″ are each independently hydrogen, optionally substituted C 1-3 Alkyl, optionally substituted C 3-6 cycloalkyl or an optionally substituted 5-6 membered heterocyclic group; preferably, R' is hydrogen, R" is hydrogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl, hydroxy substituted C 1-3 Alkyl, oxo C 1-3 Alkyl or 3-6 membered heterocyclic group.
[0086] In a preferred embodiment, in the -C(O)-NR'R" group described herein, R' and R" are each independently H, C 1-4 Alkyl or C 3-6 In a further preferred embodiment, R' is hydrogen, R" is hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl or deuterated C 1-3 alkyl.
[0087] In one or more embodiments of the compounds of formula IIIa of the present invention, the Z ring is: wherein * indicates the position where the Z ring is connected to the rest of the compound; A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are both CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; B1, B2, B3, B4, R' and R" are as described in any embodiment herein.
[0088] In one or more embodiments of the compound of formula IIIc of the present invention, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 and at least one of R2 and R2' is a non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; B1, B2, B3, B4, R' and R" are as described in any embodiment herein.
[0089] In one or more embodiments of the compound of formula IIIc of the present invention, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6A1 is CH, A2 is CR1 and A3 is CH, or A1 and A2 are CH, A3 is CR1, wherein R1 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; B1, B2, B3, B4, R' and R" are as described in any embodiment herein.
[0090] One group of preferred compounds of formula I of the present invention is represented by compounds represented by formula IV (including formula IVa, IVb, IVc and IVd) or stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts thereof, or mixtures thereof, or prodrugs thereof: wherein Z1, Z2, Z3 and R″ are as described in any of the preceding embodiments; R7 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted carbocyclyl, optionally substituted alkenyl, and optionally substituted alkynyl; R8, R9 and R 10 Each is independently selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, and optionally substituted carbocyclyl.
[0091] In one or more embodiments of the compound represented by Formula IV (including Formula IVa, IVb, IVc and IVd), the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl and optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 Preferably, R2, R2' and R3 are each as described in any of the above embodiments.
[0092] In one or more embodiments of the compounds of formula IVb and IVc, the Z ring is selected from the following groups: wherein R2 and R2' are as described in any embodiment herein; preferably, in these embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one of R1 is halogen. In some embodiments, A3 is CR1, and R1 is halogen. In some embodiments, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, and A3 is CH; or A1 and A2 are both CH, A3 is CR1, and R1 is halogen.
[0093] In one or more embodiments of the compound represented by Formula IV (including Formula IVa, IVb, IVc and IVd), R7 is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl or halogen.
[0094] In one or more embodiments of the compound represented by Formula IV (including Formula IVa, IVb, IVc and IVd), R8, R9 and R 10 are independently hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, preferably, R8, R9 and R 10 are independently hydrogen, halogen or C 1-3 Alkyl; preferably, R8, R9 and R 10 At least one of them is a non-hydrogen substituent, preferably the non-hydrogen substituent is a halogen. In one or more embodiments, R8 is a halogen or C 1-3 Alkyl, R9 and R 10 are CH; or R8 is H, R9 is halogen or C 1-3 Alkyl, R 10 is CH; or R8 and R9 are both CH, R 10 Halogen or C 1-3 In some embodiments, R8 and R 10 At least one of them is halogen, preferably at least R 10 A halogen such as fluorine.
[0095] In one or more embodiments of the compounds of Formula IV (including Formula IVa, IVb, IVc and IVd), R″ is hydrogen, optionally substituted C 1-4 Alkyl, optionally substituted C3-6 Cycloalkyl or optionally substituted 3-6 membered heterocyclic group, preferably hydrogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl or 3-6 membered heterocyclic group.
[0096] In one or more embodiments of the compounds of formula IVa of the present invention, ring Z is: Wherein, * indicates the position where the Z ring is connected to the rest of the compound; R8 is H, R9 and R 10 One of them is halogen or C 1-3 alkyl, another is H; R7 and R″ are as described in any embodiment herein.
[0097] In some embodiments of Formula IVc, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 and at least one of R2 and R2' is a non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 Cycloalkyl; R8, R9 and R 10 Any one of them is halogen or C 1-3 alkyl, the rest are H; preferably, R8 is halogen or C 1-3 Alkyl, R9 and R 10 are CH; or R8 is H, R9 is halogen or C 1-3 Alkyl, R 10 is CH; or R8 and R9 are both CH, R 10 Halogen or C 1-3 Alkyl. R7 and R" are as described in any embodiment herein.
[0098] In some embodiments of Formula IVc, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R8 is H, R9 and R 10 One of them is halogen or C 1-3 alkyl, another is H; R7 and R″ are as described in any embodiment herein.
[0099] One group of preferred compounds of formula I of the present invention is represented by compounds represented by formula V (including formula Va, Vb, Vc and Vd) or stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts thereof, or mixtures thereof, or prodrugs thereof: Among them, Z1, Z2, Z3, R8, R9, R 10 , B1, B2, B3 and B4 are as described in any of the preceding embodiments; Ring D is an optionally substituted 4- to 12-membered N-containing heterocyclic group; the N-containing heterocyclic group is selected from a 4-12-membered monocyclic group or a 5-12-membered spirocyclic group containing at least one N atom, and the N-containing heterocyclic group may further include 1-4 heteroatoms selected from N, O or S, and may be optionally further substituted by one or more R"'; W is a bond, O or -NR'-; Q is optionally substituted aminoacyl (-C(O)-NR'R") or optionally substituted heteroaryl; R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R'' is selected from halogen, hydroxy, cyano or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally further substituted by one or more substituents selected from hydroxy, halogen or cyano; or, any two R''s may form a 3-8 membered ring.
[0100] In one or more embodiments of the compound represented by Formula V (including Formula Va, Vb, Vc and Vd), the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 Preferably, R2, R2' and R3 are each as described in any of the above embodiments.
[0101] In one or more embodiments of the compounds of formula Vb and Vc, the Z ring is selected from the following groups: wherein R2 and R2' are as described in any embodiment herein; preferably, in these embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one of R1 is halogen. In some embodiments, A3 is CR1, and R1 is halogen. In some embodiments, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, and A3 is CH; or A1 and A2 are both CH, A3 is CR1, and R1 is halogen.
[0102] In one or more embodiments of the compound represented by Formula V (including Formula Va, Vb, Vc and Vd), R8, R9 and R 10 are independently hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, preferably, R8, R9 and R 10 are independently hydrogen, halogen or C 1-3 Alkyl; preferably, R8, R9 and R 10 At least one of them is a non-hydrogen substituent, preferably the non-hydrogen substituent is a halogen. In one or more embodiments, R8 is a halogen or C 1-3 Alkyl, R9 and R 10 are CH; or R8 is H, R9 is halogen or C 1-3 Alkyl, R 10 is CH; or R8 and R9 are both CH, R 10Halogen or C 1-3 In some embodiments, R8 and R 10 At least one of them is halogen, preferably at least R 10 A halogen such as fluorine.
[0103] In one or more embodiments of the compounds of Formula V (including Formula Va, Vb, Vc and Vd), L is optionally substituted with 1-2 C 1-3 Alkyl substituted alkylene, more preferably optionally substituted with 1-2 C 1-3 Alkyl substituted C 1-3 Alkylene, preferably optionally substituted with 1-2 C 1-3 Alkyl substituted methylene.
[0104] In one or more embodiments of the compound represented by formula V (including formula Va, Vb, Vc and Vd), ring D is an optionally substituted 4-7 membered monocyclic ring containing at least 1 N atom; preferably, ring D is an optionally substituted piperazinyl, piperidinyl, dihydropyridinyl or pyrrolidinyl. When ring D is substituted, the number of substituents can be 1-3, which can be selected from halogen, hydroxyl, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl.
[0105] In one or more embodiments of the compound represented by Formula V (including Formula Va, Vb, Vc and Vd), Ring D is selected from the following groups: Preferably, ring D is Among them, *1 represents the connection position between ring D and L; *2 represents the connection position between ring D and W.
[0106] In one or more embodiments of the compound represented by Formula V (including Formula Va, Vb, Vc, and Vd), W is a bond or -NH-.
[0107] In one or more embodiments of the compounds shown in formula V (including formula Va, Vb, Vc and Vd), ring D is an optionally substituted piperazinyl, piperidinyl or dihydropyridinyl, and W is a bond. In one or more embodiments, ring D is an optionally substituted pyrrolidinyl, and W is -NH-.
[0108] In one or more embodiments of the compound represented by Formula V (including Formula Va, Vb, Vc and Vd), B1, B2, B3 and B4 are each independently selected from N and CR7, wherein R7 is preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, more preferably R7 is hydrogen, C 1-3Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 In a preferred embodiment, B1 and B2 are both CH, B3 is N, B4 is CR7, wherein R7 is preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, more preferably R7 is hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl.
[0109] In one or more embodiments of the compound represented by Formula V (including Formula Va, Vb, Vc and Vd), Q is -C(O)-NR'R", wherein R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 In one or more embodiments, Q is optionally substituted with 1-3 halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy and halogenated C 1-3 The substituent of the alkoxy group is a 5-membered heteroaryl group substituted with a pyrrolyl group, a pyrazolyl group, an imidazolyl group or a triazolyl group.
[0110] In one or more embodiments of the compounds of formula Va of the present invention, the Z ring is: Wherein, * indicates the position where the Z ring is connected to the rest of the compound; R8 is H, R9 and R 10 One of them is halogen or C 1-3 Alkyl, another is H; L, Ring D, W, B1, B2, B3, B4 and Q are as described in any embodiment herein.
[0111] In some embodiments of Formula Vc, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 and at least one of R2 and R2' is a non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 Cycloalkyl; R8, R9 and R 10 Any one of them is halogen or C 1-3 alkyl, the rest are H; preferably, R8 is halogen or C 1-3 Alkyl, R9 and R 10 are CH; or R8 is H, R9 is halogen or C 1-3 Alkyl, R 10 is CH; or R8 and R9 are both CH, R 10 Halogen or C 1-3 L, ring D, W, B1, B2, B3, B4 and Q are as described in any of the above embodiments.
[0112] In some embodiments of Formula Vc, the Z ring is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R8 is H, R9 and R 10 One of them is halogen or C 1-3 Alkyl, another is H; L, ring D, W, B1, B2, B3, B4 and Q are as described in any of the previous embodiments.
[0113] One group of preferred compounds of formula I of the present invention is represented by compounds represented by formula VI (including formula VIa, VIb and VIc) or their stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts, or mixtures thereof, or prodrugs thereof: wherein Z1, Z2, Z3, R7, D1 and Q are as described in any of the preceding embodiments; R7' is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl; R9 and R 10 are independently hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, and R9 and R 10 At least one of them is not hydrogen; D1 is N or CR 11 ; R 11 is H, halogen, cyano, hydroxyl, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy.
[0114] In one or more embodiments of the compound represented by Formula VI (including Formulas VIa, VIb and VIc), the Z ring is selected from the following groups: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 R3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen and optionally substituted C 1-3 Preferably, R2, R2' and R3 are each as described in any of the above embodiments.
[0115] In one or more embodiments of the compounds of formula IVb and IVc, the Z ring is selected from the following groups: wherein R2 and R2' are as described in any embodiment herein; preferably, in these embodiments, at least one of A2 and A3 is CR1, and R1 is halogen. In some embodiments, A2 and A3 are both CR1, and at least one of R1 is halogen. In some embodiments, A3 is CR1, and R1 is halogen. In some embodiments, A1 is CR1, A2 and A3 are CH; or A1 is CH, A2 is CR1, and A3 is CH; or A1 and A2 are both CH, A3 is CR1, and R1 is halogen.
[0116] In one or more embodiments of the compound represented by Formula VI (including Formula VIa, VIb and VIc), R9 is hydrogen, R 10 Halogen or C 1-3 In one or more embodiments, R9 is halogen or C 1-3 Alkyl, R 10 In some embodiments, R9 is hydrogen, R 10 is halogen; or R9 is halogen, R 10 The preferred halogen is F.
[0117] In one or more embodiments of the compound represented by Formula VI (including Formula VIa, VIb and VIc), D1 is N or CH.
[0118] In one or more embodiments of the compound represented by Formula VI (including Formula VIa, VIb and VIc), R7 and R7' are each independently hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, preferably R7 and R7' are each independently hydrogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, more preferably R7 and R7' are each independently hydrogen, C 1-3 Alkyl, halogenated C 1-3 Preferably, at least one of R7 and R7' is not hydrogen. Preferably, R7 is C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, R7' is hydrogen; or R7 is hydrogen, R7' is C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 More preferably, R7 is C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, R7' is hydrogen.
[0119] In one or more embodiments of the compound represented by Formula VI (including Formula VIa, VIb and VIc), Q is -C(O)-NR'R" as described in any of the above embodiments, wherein R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 In one or more embodiments, Q is optionally substituted with 1-3 halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy and halogenated C 1-3 The substituent of the alkoxy group is a 5-membered heteroaryl group substituted with a substituent, and the 5-membered heteroaryl group is preferably a pyrrolyl group, a pyrazolyl group, an imidazolyl group or a triazolyl group.
[0120] In one or more embodiments of the compound of Formula VIa, one of Z1, Z2 and Z3 is O, and the other two are CR1, wherein R1 is selected from H, halogen and C 1-3 Preferably, Z1 is O, and Z2 and Z3 are CH. Preferably, in these embodiments, R9 is a non-hydrogen substituent, such as halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F. Further preferably, in these embodiments, R 10 is H, halogen or C 1-3 Alkyl, preferably H; D1 is N or CH; R7 is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H, halogen, halogenated C 1-3 Alkyl or C 1-3 Alkyl; R7' is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H or halogen; Q is said -C(O)-NR'R" or optionally substituted by 1 or 2 halogen and C 1-3 Alkyl-substituted pyrrolyl, pyrazolyl, imidazolyl or triazolyl, wherein R′ and R″ are each independently selected from hydrogen, C 1-4 Alkyl or C 3-6 Cycloalkyl.
[0121] In one or more embodiments of the compound of formula VIa, one of Z1, Z2 and Z3 is O, and the other two are CR1. Preferably, Z1 is O, Z2 and Z3 are CH; R1 is selected from H, halogen and C 1-3 Alkyl; R 10 is a non-hydrogen substituent, such as halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; R9 is H, halogen or C 1-3 Alkyl, preferably H; D1 is N or CH; R7 is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H, halogen, halogenated C 1-3 Alkyl or C 1-3 Alkyl; R7' is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H or halogen; Q is said -C(O)-NR'R" or optionally substituted by 1 or 2 halogen and C 1-3 Alkyl-substituted pyrrolyl, pyrazolyl, imidazolyl or triazolyl, wherein R′ and R″ are each independently selected from hydrogen, C 1-4 Alkyl or C 3-6 Preferably, these embodiments do not include R9 being H, R 10 The compound wherein R7 is methyl, D1 is N, R7' is H, Q is -C(O)-NH(CH3) or -C(O)-NH(CD3), and R9 is H, R 10 The compound is F, R7 is F, D1 is N, R7' is H, and Q is -C(O)-NH(CH3) or -C(O)-NH(CD3).
[0122] In some embodiments of Formula VIc, Ring Z is: Wherein, * represents the position where the Z ring is connected to the rest of the compound; R2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R2' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, cyano, optionally substituted C1-3 Alkyl and optionally substituted C 3-6 and at least one of R2 and R2' is a non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 Cycloalkyl; R9 and R 10 One of them is halogen or C 1-3 Alkyl, the other is hydrogen; D1 is N or CH; R7 is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H, halogen, halogenated C 1-3 Alkyl or C 1-3 Alkyl; R7' is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H or halogen; Q is said -C(O)-NR'R" or optionally substituted by 1 or 2 halogen and C 1-3 Alkyl-substituted pyrrolyl, pyrazolyl, imidazolyl or triazolyl, wherein R′ and R″ are each independently selected from hydrogen, C 1-4 Alkyl or C 3-6 Cycloalkyl.
[0123] In some embodiments of Formula VIc, Ring Z is: wherein R2' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R8 is H, R9 and R 10 One of them is halogen or C 1-3 Alkyl, another is H; D1 is N or CH; R7 is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H, halogen, halogenated C 1-3 Alkyl or C 1-3 Alkyl; R7' is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H or halogen; Q is said -C(O)-NR'R" or optionally substituted by 1 or 2 halogen and C 1-3Alkyl-substituted pyrrolyl, pyrazolyl, imidazolyl or triazolyl, wherein R′ and R″ are each independently selected from hydrogen, C 1-4 Alkyl or C 3-6 Cycloalkyl.
[0124] One group of preferred compounds of formula I of the present invention is represented by the compound represented by formula VII or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof: Among them, R9 and R 10 As defined in Formula VI; L and Cy are as described in any of the preceding embodiments. R 12 and R 13 are independently selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, and R 12 and R 13 At least one of them is not hydrogen.
[0125] In one or more embodiments of the compound of formula VII, R 12 and R 13 are independently hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 In one or more embodiments, R 12 is hydrogen, R 13 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 In one or more embodiments, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl, R 13 is hydrogen. In a preferred embodiment, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl, R 13 More preferably, R 12 Halogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, R 13 It's hydrogen.
[0126] In one or more embodiments of the compound of formula VII, R9 is hydrogen, R 10 Is halogen or C 1-3In one or more embodiments, R9 is halogen or C 1-3 Alkyl, R 10 In some embodiments, R9 is hydrogen, R 10 is halogen; or R9 is halogen, R 10 Preferably, halogen is F.
[0127] In one or more embodiments of the compound of formula VII, L is optionally substituted with 1-2 C 1-3 Alkyl substituted alkylene, more preferably optionally substituted with 1-2 C 1-3 Alkyl substituted C 1-3 Alkylene, preferably optionally substituted with 1-2 C 1-3 Alkyl substituted methylene.
[0128] In one or more embodiments of the compound of formula VII, L is an unsubstituted alkylene group, preferably an unsubstituted C 1-3 An alkylene group, more preferably a methylene group.
[0129] In one or more embodiments of the compound of formula VII, Cy is an optionally substituted 5-7 membered nitrogen-containing heterocyclic group. Preferably, the 5-7 membered nitrogen-containing heterocyclic group is covalently linked to L via its ring nitrogen atom. Further preferably, Cy is an optionally substituted piperazinyl, piperidinyl or dihydropyridinyl. Preferably, the substituents on Cy of the compound of formula VII are selected from: halogen, optionally substituted C 1-4 Alkyl, optionally substituted C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 alkoxy, cyano, hydroxy, amino (-NR'R"), optionally substituted 6-14 membered aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 4-10 membered heterocyclyl, and optionally substituted C 3-8 Cycloalkyl; wherein the 6-14 membered aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclic group and C 3-8 Each cycloalkyl group may be independently substituted by 1 to 5 groups selected from halogen, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, C 3-6 substituted with cycloalkyl, amino (-NR'R"), aminoacyl (-C(O)-NR'R"), and carboxyl; wherein R' and R" are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C3-8 cycloalkyl or an optionally substituted 3-6 membered heterocyclyl; in a preferred embodiment, the 6-14 membered aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl and C 3-8 The substituents on the cycloalkyl group include at least aminoacyl (-C(O)-NR'R"), and optionally further include halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6 In a preferred embodiment, Cy is substituted by an optionally substituted 5-10 membered heteroaryl, preferably by an optionally substituted 5-10 membered nitrogen-containing heteroaryl (such as pyridyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrimidinyl, etc.), preferably, the 5-10 membered heteroaryl or 5-10 membered nitrogen-containing heteroaryl is at least substituted by the aminoacyl (-C(O)-NR'R"), and optionally further substituted by halogen, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl and C 3-6 Preferably, the aminoacyl group (-C(O)-NR'R") is located at the para position. In a particularly preferred embodiment, Cy is piperazinyl substituted by an optionally substituted pyridyl group, piperidinyl substituted by an optionally substituted pyridyl group, or dihydropyridinyl substituted by an optionally substituted pyridyl group, and the pyridyl group is at least substituted by the aminoacyl group (-C(O)-NR'R"). Preferably, herein, when R' and R" are substituted, the number of substituents may be 1-5, which may be selected from halogen, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy and amino etc.
[0130] One group of preferred compounds of formula I of the present invention is represented by the compound represented by formula VIII or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof: Among them, R9 and R 10 As defined in Formula VI and VII; R 12 and R 13 As defined in formula VII; Ring D and Q are as defined in formula V; R7 is as defined in formula IV and VI.
[0131] In one or more embodiments of the compound of Formula VIII, R 12 and R 13 are independently hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6In one or more embodiments, R 12 is hydrogen, R 13 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 In one or more embodiments, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl, R 13 is hydrogen. In a preferred embodiment, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl, R 13 More preferably, R 12 Halogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl, R 13 It's hydrogen.
[0132] In one or more embodiments of the compound of formula VIII, R9 is hydrogen, R 10 Is halogen or C 1-3 In one or more embodiments, R9 is halogen or C 1-3 Alkyl, R 10 In some embodiments, R9 is hydrogen, R 10 is halogen; or R9 is halogen, R 10 Preferably, halogen is F.
[0133] In one or more embodiments of the compound of formula VIII, ring D is an optionally substituted 4-7 membered monocyclic ring containing at least 1 N atom; preferably, ring D is an optionally substituted piperazinyl, piperidinyl or dihydropyridinyl. When ring D is substituted, the number of substituents can be 1-3, which can be selected from halogen, hydroxyl, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl.
[0134] In one or more embodiments of the compound of formula VIII, ring D is selected from the following groups: Preferably, ring D is Wherein, *1 indicates the connection position between ring D and methylene; *2 indicates the connection position between ring D and pyridyl.
[0135] In one or more embodiments of the compound of formula VIII, R7 is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C3-6 Cycloalkyl, preferably, R7 is hydrogen, halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl or C 3-6 Cycloalkyl.
[0136] In one or more embodiments of the compound of formula VIII, Q is -C(O)-NR'R", wherein R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 In one or more embodiments, Q is optionally substituted with 1-3 halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy and halogenated C 1-3 The substituent of the alkoxy group is a 5-membered heteroaryl group substituted with a pyrrolyl group, a pyrazolyl group, an imidazolyl group or a triazolyl group.
[0137] One group of preferred compounds of formula I of the present invention is represented by the compound represented by formula IX or its stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts, or mixtures thereof, or prodrugs thereof: wherein ring D and Q are as defined in formula V; and R7 is as defined in formula IV and VI. R 10 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy; R 12 is halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl.
[0138] In one or more embodiments of the compound of Formula IX, R 10 Halogen or C 1-3 In one or more embodiments, R 10 is halogen, preferably F.
[0139] In one or more embodiments of the compound of Formula IX, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C3-6 In a preferred embodiment, R 12 Halogen, C 1-3 Alkyl or halogenated C 1-3 alkyl.
[0140] In one or more embodiments of the compound of formula IX, ring D is an optionally substituted 4-7 membered monocyclic ring containing at least 1 N atom; preferably, ring D is an optionally substituted piperazinyl, piperidinyl or dihydropyridinyl. When ring D is substituted, the number of substituents can be 1-3, which can be selected from halogen, hydroxyl, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl.
[0141] In one or more embodiments of the compound of formula IX, ring D is selected from the following groups: Preferably, ring D is Wherein, *1 indicates the connection position between ring D and methylene; *2 indicates the connection position between ring D and pyridyl.
[0142] In one or more embodiments of the compound of formula IX, R7 is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, preferably, R7 is hydrogen, halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl or C 3-6 More preferably, R7 is halogen or C 1-3 alkyl.
[0143] In one or more embodiments of the compound of formula IX, Q is -C(O)-NR'R", wherein R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 More preferably, R' is H, and R" is C optionally substituted by 1 to 5 halogens. 1-4 Alkyl or C 3-6 Cycloalkyl.
[0144] It should be understood that although the above description of Z1, Z2, Z3, Z4, Z5, A1, A2, A3, L, Cy, R6, R7, R8, R9, R 10 , R 12 , R 13 , D1, B1, B2, B3, B4, W, Q, R′ and R″ are described separately, but each of the described features can be combined arbitrarily to form the scope of different compounds of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) of the present invention. For example, in some embodiments of the compounds of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) of the present invention.
[0145] Preferred examples of compounds of formula I include, but are not limited to: 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one (Example 1); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 2); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one (Example 3); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazolo[4,5-c]quinolin-4(5H)-one (Example 4); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[2,3-c]quinolin-4(5H)-one (Example 5); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one (Example 6); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 7); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 8); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 9) 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one (Example 10); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one (Example 11); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)oxazolo[4,5-c]quinolin-4(5H)-one (Example 12); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazolo[5,4-c]quinolin-4(5H)-one (Example 13); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)oxazolo[5,4-c]quinolin-4(5H)-one (Example 14); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[3,4-c]quinolin-4(5H)-one (Example 15); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one (Example 16); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one (Example 17); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one (Example 18); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one (Example 19); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluorothieno[3,2-c]quinolin-4(5H)-one (Example 20); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluorothieno[3,4-c]quinolin-4(5H)-one (Example 21); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluorofuro[3,2-c]quinolin-4(5H)-one (Example 22); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one (Example 23); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one (Example 24); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one (Example 25); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one (Example 26); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[4,5-c]quinolin-4(5H)-one (Example 27); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one (Example 28); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[5,4-c]quinolin-4(5H)-one (Example 29); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[5,4-c]quinolin-4(5H)-one (Example 30); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[3,4-c]quinolin-4(5H)-one (Example 31); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[4,3-c]quinolin-4(5H)-one (Example 32); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[4,5-c]quinolin-4(5H)-one (Example 33); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,5-dihydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 34); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 35); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,4-c]quinolin-4(5H)-one (Example 36); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[4,3-c]quinolin-4(5H)-one (Example 37); 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[2,3-c]quinolin-4(5H)-one (Example 38); 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one (Example 39); 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 40); 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazolo[4,5-c]quinolin-4(5H)-one (Example 41); 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 42); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[3,2-c]quinolin-4(5H)-one (Example 43); 7-((4-(2-Fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[3,2-c]quinolin-4(5H)-one (Example 44); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 45); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 46); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one (Example 47); 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one (Example 48); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 49); 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 50); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 51); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 52); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one (Example 53); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one (Example 54); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one (Example 55); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one (Example 56); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 57); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 58); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-chloro-pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 59); 7-((4-(2-Fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-chloro-pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 60); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 61); 8-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 62); 8-((4-(2-methyl-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 63); 8-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 64); 8-((4-(2-methyl-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 65); 7-((4-(2-Fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one (Example 66); 7-((4-(2-Fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one (Example 67); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one (Example 68); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one (Example 69); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one (Example 70); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one (Example 71); 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one (Example 72); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one (Example 73); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 74); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 75); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 76); 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 77); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 78); 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one (Example 79); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-cyclopenta[c]quinolin-4-one (Example 80); 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-cyclopenta[c]quinolin-4-one (Example 81); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,2-c]quinolin-4(2H)-one (Example 82); 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,2-c]quinolin-4(2H)-one (Example 83); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,4-c]quinolin-4(1H)-one (Example 84); 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,4-c]quinolin-4(1H)-one (Example 85); 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2-dihydrofuro[2,3-c]quinolin-4(5H)-one (Example 86); 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2-dihydrofuro[2,3-c]quinolin-4(5H)-one (Example 87); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 88); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 89); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 90); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 91); 6-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (Example 92); 6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one (Example 93); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluorooxazolo[5,4-c]quinolin-4(5H)-one (Example 94); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorooxazolo[5,4-c]quinolin-4(5H)-one (Example 95); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-6-fluoroisoxazolo[4,5-c]quinolin-4(5H)-one (Example 96); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-8-fluoroisoxazolo[4,5-c]quinolin-4(5H)-one (Example 97); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[4,5-c]quinolin-4(5H)-one (Example 98); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one (Example 99); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1-methyl-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one (Example 100); 7-((4-(2-(difluoromethyl)-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one (Example 101); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluorofuro[2,3-c]quinolin-4(5H)-one (Example 102); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylfuro[2,3-c]quinolin-4(5H)-one (Example 103); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-methylfuro[2,3-c]quinolin-4(5H)-one (Example 104); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chlorofuro[2,3-c]quinolin-4(5H)-one (Example 105); 7-((4-(2-fluoro-6-carbamoylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one (Example 106); 6-fluoro-7-((4-(5-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 107); 6-fluoro-7-((4-(6-(methylcarbamoyl)-2-(trifluoromethyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 108); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperidin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one (Example 109); 7-((4-(2-fluoro-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one (Example 110); 7-((4-(2-fluoro-6-(5-methyl-1H-imidazol-2-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one (Example 111); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 112); 7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 113); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one (Example 114); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[3,4-c]quinolin-4(5H)-one (Example 115); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methylfuro[2,3-c]quinolin-4(5H)-one (Example 116); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,6-difluorofuro[2,3-c]quinolin-4(5H)-one (Example 117); 7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one (Example 118); 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one (Example 119); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one (Example 120); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 121); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 122); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 123); 6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperidin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 124); 7-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 125); 7-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 126); 7-((4-(5-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 127); 7-((4-(2-cyano-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 128); 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 129); 7-((4-(2-fluoro-6-(1H-imidazol-5-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 130); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 131); 7-((4-(2-difluoromethyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 132); 7-((4-(2-trifluoromethyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 133); (R)-6-fluoro-3-methyl-7-((3-((6-(methylcarbamoyl)pyridin-3-yl)amino)pyrrolidin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 134); (R)-6-fluoro-7-((3-((2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)amino)pyrrolidin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 135); 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-10-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 136); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-10-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 137); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,7-difluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 138); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,7-difluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 139); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 140); 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (Example 141); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorooxazolo[4,5-c]quinolin-4(5H)-one (Example 142); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,4-c]quinolin-4(5H)-one (Example 143); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[3,4-c]quinolin-4(5H)-one (Example 144); 7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one (Example 145); (R)-7-((3-((6-(methylcarbamoyl)pyridin-3-yl)amino)pyrrolidin-1-yl)methyl)-6-fluorofuran[2,3-c]quinolin-4(5H)-one (Example 146); 6-fluoro-7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 147); 6-fluoro-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one (Example 148); 6-fluoro-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,4-c]quinolin-4(5H)-one (Example 149); 6-fluoro-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one (Example 150); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 151); 6-fluoro-3-methyl-7-((6-methylcarbamoyl-3',6'-dihydro-[3,4'-bipyridyl]-1'(2'H)-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 152); 6-fluoro-3-methyl-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 153); 6-Fluoro-7-((4-(2-fluoro-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 154); 6-Fluoro-7-((4-(2-chloro-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 155); (R)-6-fluoro-7-((4-(2-fluoro-6-((tetrahydrofuran-3-yl)carbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 156); 6-fluoro-3-methyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 157); 7-((4-(6-(1H-imidazol-2-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 158); 6-fluoro-7-((4-(2-fluoro-6-((methyl-d3)carbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 159); 7-((4-(2-cyclopropyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 160); 6-fluoro-7-((4-(3-fluoro-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 161); 6-fluoro-7-((4-(2-methyl-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 162); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-ethyl-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 163); 6-Fluoro-7-((4-(2-fluoro-6-cyanopyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 164); 6-Fluoro-7-((2-fluoro-6-methylcarbamoyl-3',6'-dihydro-[3,4'-bipyridyl]-1'(2'H)-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 165); (R)-6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)-3-methylpiperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 166); (R)-6-fluoro-3-methyl-7-((8-methylcarbamoyl-1,2,4a,5-tetrahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazin-3(4H)-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 167); 8-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 168); 8-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 167); 8-Fluoro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 170); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 171); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 172); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 173); 6-chloro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 174); 6-chloro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 175); 6-chloro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 176); 3,9-difluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 177); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 178); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-trifluoromethyl-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 179); 7-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 180); 7-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 181); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,8-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 182); 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,8-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 183); 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,8-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 184); 7-((4-(2-fluoro-6-((methyl-d3)carbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 185); 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 186); 7-((4-(2-cyano-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 187); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 188); 3-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 189); 3-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 190); 3-Fluoro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 191); 3-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 192); 3-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 193); 3-Fluoro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 194); 7-((4-(2-fluoro-6-cyanopyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 195); (R)-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)-3-methylpiperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 196); 7-((2-fluoro-6-methylcarbamoyl-3',6'-dihydro-[3,4'-bipyridyl]-1'(2'H)-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 197); (R)-7-((8-methylcarbamoyl-1,2,4a,5-tetrahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazin-3(4H)-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 198); 6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-3-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 199); 6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,3-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 200); 7-((4-(2-cyano-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-(trifluoromethyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 201); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-cyano-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one Example (202); 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-isopropyl-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 203); 6-fluoro-7-(1-(4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)ethyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 204); 7-Fluoro-8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)imidazo[1,5-c]quinazolin-5(6H)-one (Example 205); or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof.
[0146] Some of the compounds of the present invention may exist as stereoisomers, including optical isomers. The present invention includes all stereoisomers and racemic mixtures of such stereoisomers, as well as individual enantiomers which may be separated according to methods well known to those skilled in the art.
[0147] Examples of pharmaceutically acceptable salts include inorganic and organic acid salts, such as hydrochlorides, hydrobromides, phosphates, sulfates, citrates, lactates, tartrates, maleates, fumarates, mandelates and oxalates; and inorganic and organic base salts formed with bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine) and N-methylglucamine.
[0148] Examples of prodrugs of the compounds of the invention include simple esters of carboxylic acid-containing compounds (e.g., by reacting with C 1-4 esters obtained by condensation of hydroxyl groups (for example, by condensation of hydroxyl groups with C 1-4 Carboxylic acid, C 3-6 esters obtained by condensation of diacids or their anhydrides, such as succinic anhydride and fumaric anhydride); imines of compounds containing amino groups (for example, by reacting with C 1-4 (J. Med. Chem. 42:3657-3667 (1999)); acetals or ketal of compounds containing alcohols (e.g., those obtained by condensation with chloromethyl methyl ether or chloromethyl ethyl ether according to methods known in the art).
[0149] The compounds of the present invention can be prepared using methods known to those skilled in the art or the novel methods of the present invention. Specifically, the compounds of the present invention having formula I (including formula II, III, IV, V, VI, VII, VIII and IX) can be prepared as shown in the reaction examples in reaction scheme 1. 2-Bromothiophene-3-carboxylic acid methyl ester and (2-amino-4-(methoxycarbonyl)phenyl)boric acid undergo amine transesterification and Suzuki coupling reaction under the catalysis of sodium acetate and Pd(dppf)Cl2 to obtain the product 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-7-carboxylic acid methyl ester. 4-Oxo-4,5-dihydrothieno[3,2-c]quinoline-7-carboxylic acid methyl ester undergoes reduction reaction with LiAlH4 to obtain the product 7-(hydroxymethyl)thieno[3,2-c]quinoline-4(5H)-one. 7-(Hydroxymethyl)thieno[3,2-c]quinolin-4(5H)-one undergoes chlorination reaction with SOCl2 to obtain the product 7-(chloromethyl)thieno[3,2-c]quinolin-4(5H)-one. 7-(Chloromethyl)thieno[3,2-c]quinolin-4(5H)-one undergoes substitution reaction with N,6-dimethyl-5-(piperazin-1-yl)pyridineamide to obtain the target product 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one. Reaction Scheme 1
[0150] Other related compounds can be prepared by similar methods. For example, methyl 4-bromothiophene-3-carboxylate is used to replace methyl 2-bromothiophene-3-carboxylate to obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one. methyl 5-bromothiazole-4-carboxylate is used to replace methyl 2-bromothiophene-3-carboxylate to obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazo[4,5-c]quinolin-4(5H)-one. The target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[2,3-c]quinolin-4(5H)-one can be obtained by replacing 2-bromothiophene-3-carboxylic acid methyl 3-methyl ester. The target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furano[2,3-c]quinolin-4(5H)-one can be obtained by replacing 2-bromothiophene-3-carboxylic acid methyl 3-methyl ester. Substituting 2-bromothiophene-3-carboxylic acid methyl ester with 3-bromo-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester can obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one.
[0151] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 2. Under the catalysis of Pd(PPh3)4, furan-3-carboxylic acid methyl ester and 1,4-dibromo-2-nitrobenzene undergo Heck coupling reaction to obtain the product 2-(4-bromo-2-nitrophenyl) furan-3-carboxylic acid methyl ester. 2-(4-bromo-2-nitrophenyl) furan-3-carboxylic acid methyl ester reacts with iron powder and NH4Cl to obtain the product 7-bromofurano[3,2-c]quinolin-4(5H)-one. 7-Bromofurano[3,2-c]quinolin-4(5H)-one and tributyltinmethanol (Bu3SnCH2OH) reacted in a Stille coupling reaction catalyzed by chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2) to give the product 7-(hydroxymethyl)furano[3,2-c]quinolin-4(5H)-one. 7-(Hydroxymethyl)furano[3,2-c]quinolin-4(5H)-one reacted with SOCl2 to give the product 7-(chloromethyl)furano[3,2-c]quinolin-4(5H)-one. Under the catalysis of DIEA and KI, 7-(chloromethyl)furo[3,2-c]quinolin-4(5H)-one and N,6-dimethyl-5-(piperazin-1-yl)picolinamide underwent substitution reaction to obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one. Reaction Scheme 2
[0152] Other related compounds can be prepared by similar methods. For example, by replacing 1,4-dibromo-2-nitrobenzene with 1-bromo-2-fluoro-4-iodo-3-nitrobenzene, the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[3,2-c]quinolin-4(5H)-one can be prepared. By replacing N,6-dimethyl-5-(piperazin-1-yl)pyridinamide with 6-fluoro-N-methyl-5-(piperazin-1-yl)pyridinamide, the target compound 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[3,2-c]quinolin-4(5H)-one can be prepared.
[0153] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 3. Ethyl 2-(4-bromo-2-nitrobenzoyl)-3-(dimethylamino)acrylate reacts with hydrazine hydrate to obtain the product ethyl 5-(4-bromo-2-nitrophenyl)-1H-pyrazole-4-carboxylate. Ethyl 5-(4-bromo-2-nitrophenyl)-1H-pyrazole-4-carboxylate reacts with iron powder and AcOH to obtain the product 7-bromo-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one. Under the catalysis of 4-dimethylaminopyridine (DMAP), 7-bromo-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one reacts with di-tert-butyl dicarbonate ((Boc)2O) to obtain the product 7-bromo-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylic acid tert-butyl ester. Under the catalysis of XPhos Pd G2, 7-bromo-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylic acid tert-butyl ester reacts with Bu3SnCH2OH to obtain the product 7-(hydroxymethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one. 7-(Hydroxymethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one reacts with HBr to obtain the product 7-(bromomethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one. Under the catalysis of DMAP, 7-(bromomethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one reacts with (Boc)2O to obtain the product 7-(bromomethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylic acid tert-butyl ester. Under the catalysis of DIEA and KI, tert-butyl 7-(bromomethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate and N,6-dimethyl-5-(piperazin-1-yl)picolinamide underwent substitution reaction to obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one. Reaction Scheme 3
[0154] Other related compounds can be prepared by similar methods. For example, replacing hydrazine hydrate with methylhydrazine can obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one. Replacing 2-(4-bromo-2-nitrobenzoyl)-3-(dimethylamino)ethyl acrylate with ethyl 2-(4-bromo-3-fluoro-2-nitrobenzoyl)-3-(dimethylamino)acrylate can obtain the target compound 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one. By replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with 6-fluoro-N-methyl-5-(piperazin-1-yl)picolinamide, the target compound 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one can be obtained.
[0155] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 4. Under the catalysis of Pd(PPh3)Cl2, (2-(ethoxycarbonyl)furan-3-yl)boric acid and methyl 4-bromo-3-fluoro-5-nitrobenzoate undergo Suzuki coupling reaction to obtain the product ethyl 3-(2-fluoro-4-(methoxycarbonyl)-6-nitrophenyl)furan-2-carboxylate. Ethyl 3-(2-fluoro-4-(methoxycarbonyl)-6-nitrophenyl)furan-2-carboxylate reacts with iron powder and AcOH to obtain the product methyl 9-fluoro-4-oxo-4,5-dihydrofurano[2,3-c]quinoline-7-carboxylate. 9-Fluoro-4-oxo-4,5-dihydrofuro[2,3-c]quinoline-7-carboxylic acid methyl ester reacts with LiAlH4 to give the product 9-fluoro-7-(hydroxymethyl)furo[2,3-c]quinolin-4(5H)-one. 9-Fluoro-7-(hydroxymethyl)furo[2,3-c]quinolin-4(5H)-one reacts with HBr to give the product 7-(bromomethyl)-9-fluorofuro[2,3-c]quinolin-4(5H)-one. Under the catalysis of DIEA and KI, 7-(bromomethyl)-9-fluorofuro[2,3-c]quinolin-4(5H)-one reacts with N,6-dimethyl-5-(piperazin-1-yl)picolinamide to give the product 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one. Reaction Scheme 4
[0156] Other related compounds can be prepared by similar methods. For example, replacing (2-(ethoxycarbonyl)furan-3-yl)boronic acid with 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid methyl ester can obtain the target compound 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[2,3-c]quinolin-4(5H)-one.
[0157] The compounds of the present invention can be prepared as shown in the reaction example in reaction scheme 5. 4-Fluoro-1H-pyrazole-5-carboxylic acid reacts with SOCl2 to obtain the product 4-fluoro-1H-pyrazole-5-carbonyl chloride. Under the catalysis of lithium bis(trimethylsilyl)amide (LiHMDS), 4-fluoro-1H-pyrazole-5-carbonyl chloride reacts with 3-amino-4-fluorobenzoic acid methyl ester to obtain the product 4-fluoro-3-(4-fluoro-1H-pyrazole-5-carboxamide)benzoic acid methyl ester. Under the catalysis of K2CO3, 4-fluoro-3-(4-fluoro-1H-pyrazole-5-carboxamide)benzoic acid methyl ester undergoes a ring-closing reaction to obtain the product 3-fluoro-4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carboxylic acid methyl ester. 3-Fluoro-4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carboxylic acid methyl ester reacts with LiAlH4 to obtain the product 3-fluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one. 3-Fluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one reacts with SOCl2 to obtain the product 7-(chloromethyl)-3-fluoropyrazolo[1,5-a]quinoxaline-4(5H)-one. Under the catalysis of DIEA and KI, 7-(chloromethyl)-3-fluoropyrazolo[1,5-a]quinoxaline-4(5H)-one reacts with 6-fluoro-N-methyl-5-(piperazin-1-yl)picolinamide to obtain the product 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoropyrazolo[1,5-a]quinoxaline-4(5H)-one. Reaction Scheme 5
[0158] Other related compounds can be prepared by similar methods. For example, replacing 4-fluoro-1H-pyrazole-5-carboxylic acid with 4-fluoro-3-methyl-1H-pyrazole-5-carboxylic acid can obtain the target compound 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one. Replacing 4-fluoro-1H-pyrazole-5-carboxylic acid with 1H-imidazole-5-carboxylic acid can obtain the target compound 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one.
[0159] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 6. 2-Amino-4-bromo-3-fluorobenzonitrile reacts with chlorosulfonyl isocyanate to obtain 4-amino-7-bromo-8-fluoroquinazolin-2(1H)-one. Under the catalysis of sodium acetate, 4-amino-7-bromo-8-fluoroquinazolin-2(1H)-one reacts with chloroacetaldehyde to obtain 8-bromo-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one. Under the catalysis of XPhos Pd G2, 8-bromo-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one reacts with Bu3SnCH2OH to obtain 7-fluoro-8-(hydroxymethyl)imidazo[1,2-c]quinazolin-5(6H)-one. 7-Fluoro-8-(hydroxymethyl)imidazo[1,2-c]quinazolin-5(6H)-one reacts with phosphorus tribromide to give 8-(bromomethyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one. Under the catalysis of DIEA and KI, 8-(bromomethyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one reacts with N,6-dimethyl-5-(piperazin-1-yl)pyridineamide hydrochloride to give the final product 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one. Reaction Scheme 6
[0160] Other related compounds can be prepared by similar methods. For example, replacing N,6-dimethyl-5-(piperazin-1-yl)pyridineamide with 6-fluoro-N-methyl-5-(piperazin-1-yl)pyridineamide can obtain the target compound 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one. Replacing N,6-dimethyl-5-(piperazin-1-yl)pyridineamide with N-ethyl-6-fluoro-5-(piperazin-1-yl)pyridineamide can obtain the target compound 8-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one. The target compound 8-((4-(2-methyl-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one was obtained by replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with N-ethyl-6-methyl-5-(piperazin-1-yl)picolinamide. The target compound 8-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one was obtained by replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with N-cyclopropyl-6-fluoro-5-(piperazin-1-yl)picolinamide. Replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with N-cyclopropyl-6-methyl-5-(piperazin-1-yl)picolinamide can produce the target compound 8-((4-(2-methyl-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one.
[0161] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 7. Under the catalysis of Pd(PPh3)Cl2, (2-(ethoxycarbonyl)furan-3-yl)boronic acid and 1,4-dibromo-2-fluoro-3-nitrobenzene undergo Suzuki coupling reaction to obtain the product 3-(4-bromo-3-fluoro-2-nitrophenyl)furan-2-carboxylic acid ethyl ester. 3-(4-bromo-3-fluoro-2-nitrophenyl)furan-2-carboxylic acid ethyl ester reacts with iron powder and AcOH to obtain the product 7-bromo-6-fluorofurano[2,3-c]quinolin-4(5H)-one. In the presence of chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos PdG2), 7-bromo-6-fluorofurano[2,3-c]quinolin-4(5H)-one and tributyltinmethanol (Bu3SnCH2OH) underwent Stille coupling reaction to give the product 6-fluoro-7-(hydroxymethyl)furano[2,3-c]quinolin-4(5H)-one. 6-Fluoro-7-(hydroxymethyl)furano[2,3-c]quinolin-4(5H)-one reacted with HBr to give the product 7-(bromomethyl)-6-fluorofurano[2,3-c]quinolin-4(5H)-one. Under the catalysis of DIEA and KI, 7-(bromomethyl)-9-fluorofuro[2,3-c]quinolin-4(5H)-one reacts with 6-fluoro-N-ethyl-5-(piperazin-1-yl)picolinamide hydrochloride to obtain the product 7-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one. Reaction Scheme 7
[0162] Other related compounds can be prepared by similar methods. For example, by replacing 6-fluoro-N-ethyl-5-(piperazin-1-yl) pyridineamide with 6-fluoro-N-cyclopropyl-5-(piperazin-1-yl) pyridineamide, the target compound 7-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one can be prepared. By replacing 6-fluoro-N-ethyl-5-(piperazin-1-yl) pyridineamide with 6-chloro-N-methyl-5-(piperazin-1-yl) pyridineamide, the target compound 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one can be prepared.
[0163] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 8. 4-Fluoro-1H-pyrazole-5-carboxylic acid reacts with SOCl2 to obtain the product 4-fluoro-1H-pyrazole-5-carbonyl chloride. 4-Fluoro-1H-pyrazole-5-carbonyl chloride reacts with 3-bromo-2,6-difluoroaniline under the catalysis of lithium bistrimethylsilylamide (LiHMDS) to obtain the product N-(3-bromo-2,6-difluorophenyl)-4-fluoro-1H-pyrazole-5-carboxamide. N-(3-bromo-2,6-difluorophenyl)-4-fluoro-1H-pyrazole-5-carboxamide reacts with K2CO3 to obtain the product 7-bromo-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one. Under the catalysis of XPhos Pd G2, 7-bromo-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one and Bu3SnCH2OH underwent Stille coupling reaction to obtain the product 3,6-difluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one. 3,6-difluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one reacted with HBr to obtain the product 7-(bromomethyl)-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one. Under the catalysis of DIEA and KI, 7-(bromomethyl)-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one reacts with N,6-dimethyl-5-(piperazin-1-yl)picolinamide to obtain the final product 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one. Reaction Scheme 8
[0164] Other related compounds can be prepared by similar methods. For example, by replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with 6-fluoro-N-methyl-5-(piperazin-1-yl)picolinamide, the target compound 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one can be prepared. By replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with 6-chloro-N-methyl-5-(piperazin-1-yl)picolinamide, the target compound 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one can be prepared. By replacing N,6-dimethyl-5-(piperazin-1-yl)picolinamide with 5-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-N-methylpicolinamide, the target compound 7-((2-(6-(methylcarbamoyl)pyridin-3-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one can be obtained.
[0165] The compounds of the present invention can be prepared as shown in the reaction example in Reaction Scheme 9. 4-Bromo-3-fluoro-2-nitroaniline reacts with NaNO2, HCl and SnCl2·2H2O to give the product (4-bromo-3-fluoro-2-nitrophenyl)hydrazine. (4-Bromo-3-fluoro-2-nitrophenyl)hydrazine reacts with methyl 4-(dimethylamino)-3-methyl-2-oxobut-3-enoate and AcOH to give the product methyl 1-(4-bromo-3-fluoro-2-nitrophenyl)-4-methyl-1H-pyrazole-5-carboxylate. Methyl 1-(4-bromo-3-fluoro-2-nitrophenyl)-4-methyl-1H-pyrazole-5-carboxylate reacts with Fe and AcOH to give the product 7-bromo-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one. Under the catalysis of XPhos Pd G2, 7-bromo-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one and Bu3SnCH2OH underwent Stille coupling reaction to obtain the product 6-fluoro-7-(hydroxymethyl)-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one. 6-Fluoro-7-(hydroxymethyl)-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one reacted with HBr to obtain the product 7-(bromomethyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one. Under the catalysis of K2CO3 and KI, 7-(bromomethyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one was reacted with N-(2,2-difluoroethyl)-6-fluoro-5-(piperazin-1-yl)picolinamide to give the final product 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one. Reaction Scheme 9
[0166] Other related compounds can be prepared by similar methods. For example, replacing N-(2,2-difluoroethyl)-6-fluoro-5-(piperazin-1-yl)picolinamide with 6-chloro-N-methyl-5-(piperazin-1-yl)picolinamide can produce the target compound 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one. By replacing N-(2,2-difluoroethyl)-6-fluoro-5-(piperazin-1-yl)picolinamide with 6-(difluoromethyl)-N-methyl-5-(piperazin-1-yl)picolinamide, the target compound 7-((4-(2-difluoromethyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one can be obtained. By replacing N-(2,2-difluoroethyl)-6-fluoro-5-(piperazin-1-yl)picolinamide with N-methyl-5-(piperazin-1-yl)-6-(trifluoromethyl)picolinamide, the target compound 7-((4-(2-trifluoromethyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one can be obtained. By replacing N-(2,2-difluoroethyl)-6-fluoro-5-(piperazin-1-yl)picolinamide with 5-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-N,6-dimethylpicolinamide, the target compound 7-((2-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one can be obtained.
[0167] An important aspect of the present invention is the discovery that compounds of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) are PARP inhibitors, especially selective PARP1 inhibitors. Therefore, compounds of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) or their stereoisomers, tautomers, N-oxides, hydrates, solvates, isotope-labeled compounds or pharmaceutically acceptable salts, or mixtures thereof, or prodrugs thereof can be used to treat a variety of diseases or conditions that respond to inhibition of PARP activity (especially PARP1 activity), or to prepare drugs for treating diseases or conditions that respond to inhibition of PARP activity (especially PARP1 activity).
[0168] Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the degradation of the second messengers cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP). PDEs mediate a variety of physiological processes, including ion channel function, muscle contraction, central nervous system (CNS) function, apoptosis, glycogenolysis, and gluconeogenesis. However, PDE dysfunction has been associated with various neurological and cardiovascular diseases, chronic obstructive pulmonary disease (COPD), and cancer development (Leroy et al., 2018 Circulation 138:2003-2006; Johnson et al., Lancet 2001, 358:256-257; Lee et al., 2015 Nature 519:472-476). It is reported that PDE3 inhibitors can increase cardiac contractility and heart rate and reduce blood pressure (Young et al., 1988 Drugs 36: 158-192); PDE3 inhibition can lead to myocardial lesions (myocyte necrosis with inflammatory cell infiltration) and vascular lesions of the mesentery, spleen and pancreas in rats (Zhang et al., 2002 Mol Pharmacol 62: 514-520; Aguirre et al., 2010 Toxicologic Pathology, 38: 416-428). Another important aspect of the present invention is that the selectivity of the compounds of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) of the present invention for PARP1 is significantly improved, and the inhibitory activity against PDE3A is significantly reduced, especially A2 and / or A3 are CR1 and R1 is halogen, especially F, and / or R9 and / or R 10 A compound of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) wherein R 10 The compounds of formula VII, VIII and IX which are halogens, especially F, have very low inhibitory activity against PDE3A. Therefore, the compounds of the present invention have low off-target side effects and low toxicity, and are more suitable for clinical application and combined use with other drugs.
[0169] In the present invention, the disease or condition responsive to the inhibition of PARP activity (especially PARP1 activity) includes cancer. Cancer can be a solid tumor or a blood tumor, including but not limited to liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphatic leukemia, chronic lymphatic leukemia, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, Wilms' tumor, cervical cancer, testicular cancer, soft tissue sarcoma, primary macroglobulinemia, bladder cancer, chronic myeloid leukemia, primary brain cancer, malignant melanoma, non-small cell lung cancer, small cell lung cancer, gastric cancer, colon cancer, Intestinal cancer, malignant pancreatic insulinoma, malignant carcinoid cancer, choriocarcinoma, mycosis fungoides, head and neck cancer, osteogenic sarcoma, pancreatic cancer, acute myeloid leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary neoplasia, thyroid cancer, esophageal cancer, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial cancer, polycythemia vera, essential thrombocythemia, adrenocortical carcinoma, skin cancer and prostate cancer. Preferably, the cancer is responsive to inhibition of PARP activity (especially PARP1 activity).
[0170] Therefore, the present invention provides a method for treating or preventing a disease or condition responsive to inhibition of PARP activity (especially PARP1 activity), the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I (including Formula II, III, IV, V, VI, VII, VIII and IX) or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I (including Formula II, III, IV, V, VI, VII, VIII and IX) or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof. In the present invention, the subject includes mammals, more specifically humans.
[0171] When implementing the treatment method of the present invention, an effective amount of a pharmaceutical preparation is administered to a patient with one or more of these symptoms. The pharmaceutical preparation contains an effective therapeutic concentration of a compound of formula I (including formulas II, III, IV, V, VI, VII, VIII and IX) and is formulated for oral, intravenous, local or external administration for the treatment of cancer and other diseases. The dosage is an amount that effectively improves or eliminates one or more symptoms. For the treatment of a specific disease, an effective amount is an amount sufficient to improve or alleviate the symptoms associated with the disease in some way. Such a dosage can be administered as a single dose, or it can be administered according to an effective treatment regimen. The dosage may cure the disease, but administration is usually to improve the symptoms of the disease. Repeated administration is generally required to achieve the desired symptom improvement.
[0172] In another embodiment, a pharmaceutical composition is provided, which contains a compound of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) or its stereoisomers, tautomers, N-oxides, hydrates, solvates, isotopically labeled compounds or pharmaceutically acceptable salts, or mixtures thereof, or prodrugs thereof, which are PARP inhibitors.
[0173] Another embodiment of the present invention relates to a pharmaceutical composition that can effectively treat cancer, wherein the compound of formula I (including formula II, III, IV, V, VI, VII, VIII and IX) containing a PARP inhibitor, or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof, is used in combination with at least one known anticancer drug or a pharmaceutically acceptable salt of an anticancer drug. In particular, it is used in combination with other anticancer drugs related to DNA damage and repair mechanisms, such as ATM inhibitors, ATR inhibitors, Wee1 inhibitors; HDAC inhibitors vorinostat, romidepsin, panobinostat and belinostat, etc. And in combination with other anticancer drugs related to cell division, including Chk1 / 2 inhibitors, CDK4 / 6 inhibitors such as palbociclib, DNA-PK inhibitors, etc. And in combination with other targeted anticancer drugs, including USP1 inhibitors, PRMT5 inhibitors, Polθ inhibitors, RAD51 inhibitors, etc.Other known anticancer drugs that can be used in anticancer combination therapy include, but are not limited to, alkylating agents such as busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin and carboplatin; topoisomerase I inhibitors such as camptothecin, irinotecan and topotecan; topoisomerase II inhibitors such as doxorubicin, epirubicin, aclarubicin, mitoxantrone, methylhydroxyellipticine and menthopop; RNA / DNA antimetabolites such as 5-azacytidine, gemcitabine, 5-fluorouracil and methotrexate; DNA antimetabolites such as 5-fluoro-2′-deoxyuridine, fludarabine, nelarabine, cytarabine, pralatrexate, pemetrexed, hydroxyurea and thioguanine; antimitotic agents such as colchicine, vinblastine alkali, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel and docetaxel; antibodies such as monoclonal antibodies, panitumumab, neltuzumab, nivolumab, pembrolizumab, ramucirumab, bevacizumab, pertuzumab, trastuzumab, cetuximab, obinutuzumab, ofatumumab, rituximab, alemtuzumab, ibritumomab tiuxetan, tositumomab, brentuximab, daratumumab, elotuzumab, ofatumumab, dinutuximab, blinatumomab, ipilimumab, avastin, herceptin and rituximab; antibody-drug conjugates (ADCs) such as trastuzumab-emtansine conjugate T-DM1, humanized anti-HER2 antibody-drug conjugate Trastuzumab Deruxtecan, Trastuzumab Emtansine, Humanized anti-TROP2 monoclonal antibody-drug conjugate Datopotamab Deruxtecan, Gemtuzumab Ozogamicin, CD30-directed antibody-drug conjugate Brentuximab Vedotin, Inotuzumab Ozogamicin, Sacituzumab govitecan, Enfortumab Vedotin, and Belantamab Mafodotin; kinase inhibitors such as imatinib, gefitinib, erlotinib, osimertinib, afatinib, ceritinib, alectinib, crizotinib, erlotinib, lapatinib, sorafenib, regorafenib, vemurafenib, dabrafenib, aflibercept, sunitinib, nilotinib, dasatinib, bosutinib, pralsetinib, ibrutinib, cabozantinib, lenvatinib, vandetanib, trametinib, cobimetinib, axitinib, temsirolimus, idelalisib, pazopanib, tecansicum, and everolimus.Other known anticancer drugs that can be used in anticancer combination therapy include tamoxifen, letrozole, fulvestrant, mitoguanidine, octreotide, retinoic acid, arsenic, zoledronic acid, bortezomib, carfilzomib, ixazomib, vismodegib, sonidegi, denosumab, thalidomide, lenalidomide, venetoclax, Aldesleukin (recombinant human interleukin-2) and Sipueucel-T (prostate cancer treatment vaccine).
[0174] In practicing the method of the present invention, the compound of the present invention and at least one known anticancer drug can be administered together as a single pharmaceutical composition. In addition, the compound of the present invention can also be administered separately from at least one known anticancer drug. In one embodiment, the compound of the present invention and at least one known anticancer drug are administered at about the same time, that is, all drugs are administered at the same time or successively, as long as the compound reaches a therapeutic concentration in the blood at the same time. In another embodiment, the compound of the present invention and at least one known anticancer drug are administered according to their respective dosage regimens, as long as the compound reaches a therapeutic concentration in the blood.
[0175] Another embodiment of the present invention is a bioconjugate that is effective in inhibiting tumors and is composed of the compound. This bioconjugate that can inhibit tumors is composed of the compound and at least one known medical antibody, such as Herceptin or Rituxan, or growth factors, such as EGF or FGF, or cytokines, such as interleukin 2 or 4, or any molecule that can bind to the cell surface. The antibody and other molecules can deliver the compound to its target, making it an effective anti-cancer drug. This bioconjugate can also enhance the anti-cancer effect of medical antibodies, such as Herceptin or Rituxan.
[0176] Another embodiment of the present invention relates to a pharmaceutical composition that can effectively inhibit tumors, comprising a PARP inhibitor represented by Formula I (including Formula II, III, IV, V, VI, VII, VIII and IX), or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, in combination with radiotherapy. In this embodiment, the compound of the present invention and radiotherapy can be administered at the same time or at different times.
[0177] Another embodiment of the present invention relates to a pharmaceutical composition that can be effectively used for postoperative treatment of cancer, comprising a PARP inhibitor represented by Formula I (including Formula II, III, IV, V, VI, VII, VIII and IX), or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof. The present invention also relates to a method of treating cancer in a mammal by surgically removing a tumor and then using the pharmaceutical composition of the present invention to treat the cancer.
[0178] The pharmaceutical composition of the present invention includes a pharmaceutical preparation containing all the compounds of the present invention in an amount that can effectively achieve its intended purpose. Although each person's needs are different, those skilled in the art can determine the optimal dose of each part in the pharmaceutical preparation. Generally, the compound, or its pharmaceutically acceptable salt, is orally administered to a mammal daily in an amount of about 0.0025 to 50 mg / kg body weight. However, it is preferably administered orally at about 0.01 to 10 mg / kg per kilogram. If a known anticancer drug is also administered, its dosage should be effective to achieve its intended purpose. The optimal doses of these known anticancer drugs are well known to those skilled in the art.
[0179] The unit oral dose may include about 0.01 to 50 mg, preferably about 0.1 to 10 mg of the compound of the invention. The unit dose may be administered once or more, one or more tablets per day, each tablet containing about 0.1 to 50 mg, conveniently about 0.25 to 10 mg of the compound of the invention or its solvate.
[0180] In external preparations, the concentration of the compound of the present invention may be about 0.01 to 100 mg per gram of carrier.
[0181] The compounds of the present invention can be administered as raw drugs. The compounds of the present invention can also be administered as part of a suitable pharmaceutical preparation containing a pharmaceutically acceptable carrier (including excipients and adjuvants). These pharmaceutically acceptable carriers facilitate the processing of the compounds into pharmaceutical preparations that can be used for pharmaceutical purposes. Preferred pharmaceutical preparations, especially those oral and preferred administration types, such as tablets, lozenges and capsules, and solutions suitable for injection or oral administration, contain about 0.01% to 99%, preferably from about 0.25% to 75% of active compounds and excipients.
[0182] The scope of the present invention also includes non-toxic pharmaceutically acceptable salts of the compounds of the present invention. Acid addition salts are formed by mixing a non-toxic pharmaceutically acceptable acid solution with a solution of the compound of the present invention. The acid is, for example, hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, etc. Base addition salts are formed by mixing a non-toxic pharmaceutically acceptable base solution with a solution of the compound of the present invention. The base is, for example, sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, trishydroxymethylaminomethane, N-methyl-glucamine, etc.
[0183] The pharmaceutical preparations of the present invention can be administered to any mammal, as long as they can obtain the therapeutic effect of the compounds of the present invention. The most important of these mammals are humans and veterinary animals, although the present invention is not intended to be so limited.
[0184] The pharmaceutical preparation of the present invention can be administered by any route to achieve its intended purpose. For example, it can be administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, orally, intrathecally, intracranially, nasally or externally. Alternatively or concurrently, it can be administered orally. The dosage of the drug will be determined based on the patient's age, health and weight, the type of concurrent treatment, the frequency of treatment, and the desired therapeutic benefit.
[0185] The pharmaceutical preparations of the present invention can be manufactured in a known manner. For example, they can be manufactured by conventional mixing, granulation, tableting, dissolution, or freeze-drying processes. When manufacturing oral preparations, solid excipients and active compounds can be combined and the mixture can be selectively ground. After adding appropriate amounts of auxiliary agents as needed or necessary, the granular mixture can be processed to obtain tablets or lozenge cores.
[0186] Suitable adjuvants are in particular fillers, for example sugars such as lactose or sucrose, mannitol or sorbitol; cellulose preparations and / or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate; and binders, for example starch pastes, including corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone. If necessary, disintegrants such as the starches mentioned above, as well as carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, or alginic acid or its salts, such as sodium alginate, can be added. Auxiliary agents are in particular flow regulators and lubricants, for example, silica, talc, stearic acid or its salts, such as magnesium stearate or calcium stearate, and / or polyethylene glycol. If necessary, the tablet core can be provided with a suitable coating that can resist gastric juice. For this purpose, concentrated sugar solutions can be applied. This solution may contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and / or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. To prepare a coating resistant to gastric juices, suitable cellulose solutions may be used, for example cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate. Dyes or pigments may be added to the coating of the tablet or lozenge core, for example, for identification or to characterize the combination of active ingredient doses.
[0187] Other pharmaceutical preparations for oral administration include press-fit capsules made of gelatin and sealed soft capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The press-fit capsules may contain the active compound in the form of particles, mixed with a filler such as lactose; a binder such as starch; and / or a lubricant such as talc or magnesium stearate, and a stabilizer. In soft capsules, the active compound is preferably dissolved or suspended in a suitable liquid such as a fat or liquid paraffin, to which a stabilizer may be added.
[0188] Preparations suitable for parenteral administration include aqueous solutions of the active compound, such as solutions of water-soluble salts and alkaline solutions. In addition, oily injection suspensions of the appropriate active compound may be administered. Suitable lipophilic solvents or carriers include fats such as sesame oil, synthetic fatty acid esters such as ethyl oleate or triglycerides or polyethylene glycol 400, or hydrogenated castor oil, or cyclodextrin. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, and / or dextran. Suspension stabilizers may also be contained.
[0189] According to one aspect of the present invention, the compounds of the present invention are used in topical and parenteral formulations and are useful in the treatment of skin cancer.
[0190] The topical preparation of the present invention can be made into oil, cream, emulsion, ointment, etc. by preferably using a suitable carrier. Suitable carriers include plant or mineral oil, white mineral oil (white soft paraffin), branched fat or grease, animal fat and high molecular alcohol (grease with a concentration greater than C). 12 ). Preferred carriers are those in which the active ingredient can be dissolved. Emulsifiers, stabilizers, humectants and antioxidants may also be included, as well as agents that impart color or flavor, if desired. In addition, these topical preparations may contain transdermal penetration enhancers. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762.
[0191] Creams are preferably formulated with a mixture of mineral oil, self-emulsifying beeswax and water, mixed with the active ingredient dissolved in a small amount of oil such as almond oil. A typical cream example includes about 40 parts water, 20 parts beeswax, 40 parts mineral oil and 1 part almond oil.
[0192] Ointments can be prepared by mixing a vegetable oil containing the active ingredient, such as almond oil, with warm soft paraffin, and then allowing the mixture to cool. A typical ointment example includes about 30% by weight of almond oil and 70% by weight of white soft paraffin.
[0193] The present invention also relates to the use of the compounds of the present invention to prepare drugs for treating clinical conditions that are effective in inhibiting PARP. These drugs may include the above-mentioned pharmaceutical composition.
[0194] The following examples are illustrative, rather than limiting, methods and preparations of the present invention. Other suitable modifications and improvements to various conditions and parameters that are apparent to those skilled in the art and that are typically encountered in clinical treatment are within the spirit and scope of the present invention. Example General Notes All reagents used were of commercial quality, and solvents were dried and purified according to standard methods. Mass spectrometry samples were analyzed using a single quadrupole mass spectrometer (Platform II, Agilent 6110) with electrospray ionization. Brücker Ascend 400 NMR was used to record at 300 MHz or 400 MHz. 1 For H NMR spectra, chemical shifts are reported in ppm downfield from TMS as an internal standard (0.00 ppm), and coupling constants, J values, are reported in Hz. Example 1 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one a) Preparation of methyl 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-7-carboxylate: methyl 2-bromothiophene-3-carboxylate (170.0 mg, 0.8 mmol), 2-amino-4-(methoxycarbonyl)phenylboronic acid (214.0 mg, 0.9 mmol), sodium acetate (95.0 mg, 1.2 mmol) and Pd(dppf)Cl2 (169.0 mg, 0.2 mmol) were dissolved in DMF (15 mL), and the mixture was reacted at 120°C overnight under nitrogen protection. After the reaction was complete, the mixture was cooled to room temperature, the reaction solution was filtered and the filtrate was concentrated. The crude product was purified by preparative thin layer plate (DCM / MeOH=20 / 1) to obtain the target compound (76.7 mg, yellow solid, yield: 38%). MS (ESI): 260.00 [M+H] + . b) Preparation of 7-(hydroxymethyl)thieno[3,2-c]quinolin-4(5H)-one: Dissolve 4-oxo-4,5-dihydrothieno[3,2-c]quinoline-7-carboxylic acid methyl ester (75.0 mg, 0.3 mmol) in THF (8 mL), and add LiAlH4 (1M THF solution, 1.2 mL, 1.2 mmol) at 0°C under nitrogen protection. The mixture was warmed to room temperature and reacted for 1 hour. Then water (5 mL) was added to quench the mixture and the mixture was extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to obtain the crude target compound (60.0 mg, brown solid). MS (ESI): 232.00 [M+H] + . c) Preparation of 7-(chloromethyl)thieno[3,2-c]quinolin-4(5H)-one: 7-(hydroxymethyl)thieno[3,2-c]quinolin-4(5H)-one (60.0 mg, 0.3 mmol) was dissolved in DCM (6 mL), and DMF (2 drops) and thionyl chloride (123.5 mg, 1.0 mmol) were added at 0°C. The mixture was reacted at room temperature for 15 minutes. After the reaction was complete, the solution was concentrated to obtain the crude target compound (50.0 mg, gray solid). MS (ESI): 250.00 [M+H] + . d) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one: 7-(Chloromethyl)thieno[3,2-c]quinolin-4(5H)-one (50.0 mg, 0.2 mmol), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (56.0 mg, 0.24 mmol), KI (3.3 mg, 0.02 mmol) and DIEA (156.0 mg, 1.2 mmol) were dissolved in acetonitrile (5 mL). The mixture was reacted at 80° C. for 1.5 hours. After the reaction was complete, the solvent was removed under reduced pressure. The crude product was purified by preparative thin layer plate (DCM / MeOH=10 / 1) to give the final product (14.5 mg, white solid, 3-step yield: 11%). The compounds of Examples 2-5 can be prepared by a synthetic method similar to that of Example 1. The results are shown below. Example 6 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one a) Preparation of methyl 2-(4-bromo-2-nitrophenyl)furan-3-carboxylate: Dissolve methyl furan-3-carboxylate (1.0 g, 8.0 mmol), 1,4-dibromo-2-nitrobenzene (2.7 g, 9.6 mmol), potassium acetate (2.4 g, 24.0 mmol) and Pd(PPh3)4 (924.0 mg, 0.8 mmol) in toluene (10 mL). The reaction solution was stirred at 110°C overnight under nitrogen protection. After the reaction was complete, the reaction solution was poured into water (100 mL) and extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (PE:EA=30:1) to obtain the target compound (610 mg, yellow solid, yield: 22.6%). b) Preparation of 7-bromofurano[3,2-c]quinolin-4(5H)-one: 2-(4-bromo-2-nitrophenyl)furan-3-carboxylic acid methyl ester (610 mg, 1.8 mmol) was dissolved in EtOH (10 mL), and iron powder (503 mg, 9.0 mmol) and NH4Cl solution (NH4Cl / H2O: 481 mg / 5 mL) were added. The reaction solution was stirred at 80°C overnight. After the reaction was complete, the reaction solution was filtered, the filtrate was concentrated, the obtained product was diluted with water, and extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (PE:EA=5:1) to obtain the target compound (270 mg, white oil, yield: 57.1%). MS(ESI):263.96[M+H] + . c) Preparation of 7-(hydroxymethyl)furo[3,2-c]quinolin-4(5H)-one: 7-bromofuro[3,2-c]quinolin-4(5H)-one (270 mg, 1.03 mmol), Bu3SnCH2OH (660 mg, 2.06 mmol) and Xphos Pd G2 (78.7 mg, 0.1 mmol) were dissolved in dioxane (5 mL). The reaction was stirred at 90°C overnight under nitrogen protection. After the reaction was completed, 1M KF aqueous solution (10 mL) was added at room temperature, stirred at room temperature for 10 minutes and then filtered. The filtrate was extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (PE:EA=1:1) to obtain the target compound (120 mg, gray solid, yield: 54.3%). MS(ESI):216.25[M+H] + . d) Preparation of 7-(chloromethyl)furo[3,2-c]quinolin-4(5H)-one: Dissolve 7-(hydroxymethyl)furo[3,2-c]quinolin-4(5H)-one (100 mg, 0.46 mmol) in DCM (2 mL) and add SOCl2 (276 mg, 2.33 mmol). Stir at room temperature for 2 hours. After the reaction is complete, concentrate the solution to obtain the target compound (110 mg, white solid, crude product). MS (ESI): 234.00 [M+H] + . e) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one: 7-(chloromethyl)furo[3,2-c]quinolin-4(5H)-one (110 mg, 0.47 mmol) and N,6-dimethyl-5-(piperazin-1-yl)picolinamide (134 mg, 0.56 mmol) were dissolved in acetonitrile (5 mL), and KI (7.8 mg, 0.05 mmol) and DIEA (181.9 mg, 1.41 mmol) were added. The reaction solution was stirred at 80° C. for 1 hour under nitrogen protection. After the reaction was completed, the solvent was removed by concentration under reduced pressure, and the crude product was purified by preparative thin layer plate (DCM:MeOH=10:1) to obtain the final product (7 mg, white solid, yield: 3.5%). Example 7 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one a) Preparation of ethyl 5-(4-bromo-2-nitrophenyl)-1H-pyrazole-4-carboxylate: Dissolve ethyl 2-(4-bromo-2-nitrobenzoyl)-3-(dimethylamino)acrylate (1.0 g, 2.69 mmol) and hydrazine hydrate (50% aqueous solution, 323 mg) in acetonitrile (8 mL) and stir at 50°C for 1 hour. After the reaction is complete, concentrate the reaction solution under reduced pressure. Dilute the resulting product with water (20 mL) and extract with ethyl acetate (20 mL×3). The combined organic phases are washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product is purified by silica gel column chromatography (PE:EA=4:1) to obtain the target compound (800 mg, yellow solid, yield: 88%). MS(ESI):339.90[M+H] + . b) Preparation of 7-bromo-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: Dissolve 5-(4-bromo-2-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester (800 mg, 2.36 mmol) in AcOH (6 mL), and add iron powder (662 mg, 11.83 mmol) under nitrogen protection. The reaction solution was stirred at 80°C for 2 hours. After the reaction was complete, it was cooled to room temperature and then filtered. The obtained solid was dried under reduced pressure to obtain the target compound (400 mg, white solid, yield: 67.6%). MS (ESI): 261.95 [M+H] + . c) Preparation of tert-butyl 7-bromo-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate: 7-bromo-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (400 mg, 1.4 mmol), (Boc)2O (325 mg, 1.4 mmol) and DMAP (20 mg, 0.14 mmol) were dissolved in DMF (4 mL), and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the resultant was diluted with water (20 mL) and extracted with ethyl acetate (40 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (DCM:MeOH=10:1) to obtain the target compound (500 mg, yellow solid, yield: 73%). MS (ESI): 364.00 [M+H] + . d) Preparation of 7-(hydroxymethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: Dissolve tert-butyl 7-bromo-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate (500 mg, 1.37 mmol), Bu3SnCH2OH (881 mg, 2.7 mmol) and Xphos Pd G2 (80 mg, 0.13 mmol) in dioxane (20 mL). Stir the reaction solution at 90°C overnight under nitrogen protection. After the reaction is complete, add 1M KF aqueous solution (10 mL) at room temperature, stir at room temperature for 10 minutes and filter. The filtrate is extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (PE:EA=1:1) to obtain the target compound (450 mg, white solid, yield: 90%). MS (ESI): 316.05 [M+H] + . e) Preparation of 7-(bromomethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: 7-(hydroxymethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (450 mg, 1.3 mmol) was dissolved in 48% HBr aqueous solution (10 mL) and stirred at 85°C for 3 hours. The reaction solution was concentrated under reduced pressure, the resultant was added to acetonitrile (3 mL), and then the solvent was removed under reduced pressure to obtain the target compound (300 mg, off-white solid, crude product). MS (ESI): 275.85 [M+H] + . f) Preparation of tert-butyl 7-(bromomethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate: 7-(bromomethyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (353 mg, 1.2 mmol), (Boc)2O (287 mg, 1.3 mmol) and DMAP (20 mg, 0.14 mmol) were dissolved in DMF (4 mL), and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the resultant was diluted with water (20 mL) and extracted with ethyl acetate (40 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (DCM:MeOH=10:1) to obtain the target compound (131 mg, yellow solid, yield: 33%). MS(ESI):378.00[M+H] + . g) Preparation of tert-butyl 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate: tert-butyl 7-(bromomethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate (13 mg, 0.34 mmol), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (81 mg, 0.34 mmol), KI (10.0 mg, 0.1 mmol) and DIEA (140.0 mg, 1.0 mmol) were dissolved in acetonitrile (3 mL). The reaction solution was stirred at 80° C. for 30 min. After the reaction was completed, the reaction solution was concentrated under reduced pressure and the crude product was washed with acetonitrile to obtain the title compound (95.0 mg, white solid, yield: 52%). MS(ESI):532.25[M+H] + . h) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: tert-butyl 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline-1-carboxylate (95 mg, 0.17 mmol) was dissolved in dioxane (5 mL), and a solution of HCl in dioxane (5 mL) was added under nitrogen protection. The reaction solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by preparative thin layer plate (DCM:MeOH=10:1) to give the final product (5.0 mg, white solid, yield: 6%) The compound of Example 8 can be prepared by a synthetic method similar to that of Example 7 (Reaction Scheme 3); and Example 9 can be prepared by a synthetic method similar to that of Example 1 (Reaction Scheme 1). The results are shown below. Example 10 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one a) Preparation of methyl 3-(2-amino-4-(hydroxymethyl)phenyl)-1H-pyrrole-2-carboxylate: (3-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol (100 mg, 0.40 mmol) and methyl 3-bromo-1H-pyrrole-2-carboxylate (82 mg, 0.40 mmol) were dissolved in dioxane / water (5.5 mL, v / v=10 / 1), and K2CO3 (111 mg, 0.80 mmol) and Pd(dppf)Cl2 (29 mg, 0.04 mmol) were added. The mixture was stirred at 100°C for 16 hours under nitrogen protection. The reaction solution was filtered and the filtrate was concentrated under reduced pressure to obtain the crude target product (270 mg, brown solid), which was used directly in the next step without purification. MS (ESI): 247.10 [M+H] + . b) Preparation of 7-(hydroxymethyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one: 3-(2-amino-4-(hydroxymethyl)phenyl)-1H-pyrrole-2-carboxylic acid methyl ester (270 mg, 1.1 mmol) was dissolved in AcOH (3 mL) and stirred at room temperature for 3 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure, and the crude product was purified by PE / EA=1 / 1 (10 mL×3) beating to obtain the target compound (72 mg, black solid, yield: 30%). MS (ESI): 215.10 [M+H] + . c) Preparation of 7-(bromomethyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one: 7-(hydroxymethyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one (64 mg, 0.3 mmol) was dissolved in 48% HBr aqueous solution (5 mL) and stirred at 85°C for 3 hours. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in acetonitrile (3 mL) and concentrated to obtain the crude target compound (90 mg, gray solid). MS (ESI): 555.50 [2M+H] + . d) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one: 7-(bromomethyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one (90 mg, 0.3 mmol) and N,6-dimethyl-5-(piperazin-1-yl)picolinamide (76 mg, 0.32 mmol) were dissolved in acetonitrile (2 mL), and KI (5.4 mg, 0.03 mmol) and DIEA (126 mg, 0.97 mmol) were added. The mixture was stirred at 80°C for 0.5 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure, and the crude product was purified by preparative liquid phase purification (C18, acetonitrile / water, 30%-55%) to obtain the final product (16.2 mg, off-white solid, yield: 12%). The compound of Example 11 can be prepared by a synthetic method similar to that of Example 10. The compounds of Examples 12-13 can be prepared by a synthetic method similar to that of Example 1 (Reaction Scheme 1). The results are shown below. Embodiment 14 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)oxazolo[5,4-c]quinolin-4(5H)-one a) Preparation of 4-amino-3-hydroxy-7-(hydroxymethyl)quinolin-2(1H)-one: (3-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol (1.6 g, 7.2 mmol), ethyl 4-bromooxazole-5-carboxylate (1.8 g, 7.2 mmol), K2CO3 (1.987 g, 14.4 mmol) and Pd(dppf)Cl2 (522 mg, 0.72 mmol) were dissolved in dioxane (20 mL) and water (4 mL). The reaction mixture was stirred at 100°C overnight under nitrogen protection. The reaction mixture was concentrated to obtain the target compound (1.6 g, black oil, crude product). MS (ESI): 207.00 [M+H] + . b) Preparation of 4-amino-7-(bromomethyl)-3-hydroxyquinolin-2(1H)-one: 4-amino-3-hydroxy-7-(hydroxymethyl)quinolin-2(1H)-one (1.6 g, crude product) was dissolved in 48% HBr aqueous solution (20 mL) and stirred at 85°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the obtained product was dissolved in acetonitrile (10 mL). The solvent was removed under reduced pressure to obtain the target compound (1.6 g, black oil, crude product). MS (ESI): 268.95 [M+H] + . c) Preparation of 7-(bromomethyl)oxazolo[5,4-c]quinolin-4(5H)-one: 4-amino-7-(bromomethyl)-3-hydroxyquinolin-2(1H)-one (1.6 g, crude product) was dissolved in trimethyl orthoformate (20 mL) and stirred at 85°C for 18 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by preparative thin layer plate (EtOAc:PE=1:1) to obtain the target compound (180 mg, white solid, yield: 10%). MS (ESI): 280.95 [M+H] + . d) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)oxazolo[5,4-c]quinolin-4(5H)-one: 7-(bromomethyl)oxazolo[5,4-c]quinolin-4(5H)-one (180 mg, 0.7 mmol), N,6-dimethyl-5-(piperazin-1-yl)pyridinecarboxamide (211 mg, 0.7 mmol), KI (12 mg, 0.07 mmol) and DIEA (251.0 mg, 1.9 mmol) were added and the reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated under reduced pressure and the crude product was purified by preparative liquid phase separation to obtain the final product (4.2 mg, white solid, yield: 1.4%). MS (ESI): 433.15 [M+H] + . 1 HNMR (400MHz, DMSO-d6): δ12.14(s,1H),8.96(s,1H),8.39(s,1H),7.97(d,J=8.0Hz,1H),7.76(d,J=8.1Hz,1H),7.48(s,1H),7.4 4(d,J=8.4Hz,1H),7.32(d,J=7.9Hz,1H),3.63(s,2H),2.97-2.87(m,4H),2.76(d,J=4.6Hz,3H),2.60-2.52(m,4H),2.50(s,3H). The compounds of Examples 15-21 can be prepared by a synthetic method similar to that of Example 1 (Reaction Scheme 1); Example 22 can be prepared by a synthetic method similar to that of Example 6 (Reaction Scheme 2). Embodiment 23 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one a) Preparation of N-(4-bromo-2-nitrobenzyl)formamide: (4-bromo-2-nitrophenyl)methylamine (11.5 g, 49.8 mmol) was dissolved in ethyl formate (100.0 mL) and stirred at 45°C for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (DCM / MeOH=1 / 0-200 / 1) to give the product (10.4 g, yellow solid, yield: 90%). MS (ESI): 258.95 [M+H] + . b) Preparation of 1-(4-bromo-2-nitrophenyl)-N-methyldimethylammonium: N-(4-bromo-2-nitrobenzyl)formamide (500.0 mg, 1.9 mmol) was dissolved in THF (30.0 mL) and Burgess reagent (689.9 mg, 2.9 mmol) was added at room temperature. The reaction solution was stirred at 45°C for 1 hour. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE / EA=1 / 0-50 / 1) to obtain the product (130.0 mg, white solid, yield: 27%). MS (ESI): 479.00 [2M+H] + . c) Preparation of methyl 2-(4-bromo-2-nitrophenyl)-1H-pyrrole-3-carboxylate: Methyl acrylate (750.2 mg, 8.9 mmol) and Ag2CO3 (164.0 mg, 0.6 mmol) were dissolved in dioxane (42.0 mL) at room temperature and 1-(4-bromo-2-nitrophenyl)-N-methylmethylammonium (1.4 g, 5.9 mmol) was added. The reaction solution was stirred at 80°C for 0.5 hours. After the reaction was complete, it was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE / EA=1 / 0-5 / 1) to obtain the product (1.5 g, yellow solid, yield: 77%). MS (ESI): 324.90 [M+H] + . d) Preparation of 7-bromo-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one: 2-(4-bromo-2-nitrophenyl)-1H-pyrrole-3-carboxylic acid methyl ester (800.0 mg, 2.4 mmol) was dissolved in acetic acid (20.0 mL) at room temperature, and zinc powder (1.6 g, 24.6 mmol) was added. The reaction solution was stirred at 50°C for 3 hours. After the reaction was complete, it was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by beating with DCM (100 mL×3) to obtain the product (507.0 mg, white solid, yield: 78%). MS (ESI): 262.90 [M+H] + . e) Preparation of 7-(hydroxymethyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one: 7-bromo-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one (250.0 mg, 0.9 mmol) was dissolved in dioxane (20.0 mL) at room temperature, and (tributylstannyl)methanol (1.5 g, 4.5 mmol) and Xphos Pd G2 (74.8 mg, 0.1 mmol) were added. Stirred at 50 °C under nitrogen protection for 16 hours. After the reaction was complete, the mixture was cooled to room temperature and quenched with saturated KF solution (20.0 mL). The mixture was filtered and the solid was washed with MeOH (10.0 mL) to obtain the product (280 mg, crude, black solid). MS (ESI): 215.05 [M+H] + . f) Preparation of 7-(bromomethyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one: 7-(hydroxymethyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one (175.0 mg, 0.8 mmol) was dissolved in THF (15.0 mL) and PBr3 (442.2 mg, 1.6 mmol) was added at room temperature. The reaction solution was stirred at room temperature for 2 hours. After the reaction was complete, ice water (5.0 mL) was added to quench the reaction, and the pH was adjusted to 7-8 with a saturated NaHCO3 solution (10.0 mL), and then extracted with DCM (100.0 mL×3). Drying with anhydrous sodium sulfate, filtering, and concentration gave the product (230.0 mg, crude product, yellow oil). MS (ESI): 276.90 [M+H] + . g) 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one: 7-(bromomethyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one (230.0 mg, 0.8 mmol) was dissolved in MeCN (10.0 mL), and N,6-dimethyl-5-(piperazin-1-yl)picolinamide (291.6 mg, 1.2 mmol) and potassium carbonate (573.5 mg, 4.1 mmol) were added at room temperature. The reaction solution was stirred at 80°C for 16 hours. After the reaction was complete, it was cooled to room temperature and concentrated. The crude product was purified by preparative high performance liquid chromatography (C18, MeCN / H2O=0%-27%, 0.1% formic acid) to obtain the product (42.4 mg, yellow solid, yield: 10%). MS (ESI): 431.20 [M+H] + . 1H NMR (400MHz, CD3OD): δ8.12(d,J=8.2Hz,1H),7.89(d,J=8.4Hz,1H),7.58(d,J=1.3Hz,1H),7.55(d,J=8.4Hz,1H),7.45(dd,J=8.2,1.5Hz,1H), 7.26(d,J=3.0Hz,1H),6.84(d,J=3.0Hz,1H),4.54(s,2H),3.68-3.55( m,2H),3.51-3.38(m,4H),3.16-3.04(m,2H),2.93(s,3H),2.59(s,3H). Embodiment 24 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one The compound of Example 24 was prepared by a similar method as described in Example 23. MS (ESI): 449.20 [M+H] + . 1 HNMR (400MHz, DMSO-d6): δ11.18(s,1H),8.43-8.36(m,1H),8.08(d,J=8.3Hz,1H),7.81(d,J=8.0Hz,1H),7.53(dd,J=10.6,8.1Hz,1H),7.3 6(s,1H),7.21–7.08(m,2H),6.54(d,J=2.9Hz,1H),4.11(s,3H),3.56(s,2H),3.22-3.12(m,4H),2.72(d,J=4.8Hz,3H),2.58-2.49(m,4H). Embodiment 25 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one a) Preparation of (2-amino-4-(bromomethyl)phenyl)boronic acid: Dissolve (3-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenyl)methanol (0.5 g) in 48% HBr (10 mL) and stir at 85°C for 1 hour. Concentrate the reaction solution under reduced pressure, add acetonitrile to the residue, and concentrate again under reduced pressure. Repeat the above operation 3 times to obtain the crude product of the target compound (350 mg, orange solid). MS (ESI): 232.05 [M+H]+ . b) Preparation of (2-amino-4-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)boronic acid: (2-amino-4-(bromomethyl)phenyl)boronic acid (1.0 g, crude product) and N,6-dimethyl-5-(piperazin-1-yl)picolinamide (1.0 g, 4.4 mmol) were dissolved in acetonitrile (50 mL), and KI (72 mg, 0.4 mmol) and DIEA (1.6 g, 13.1 mmol) were added. The mixture was stirred at 80° C. for 4 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure, and the crude product was purified by preparative liquid phase to obtain the target compound (0.2 g, white solid, yield: 14%). MS (ESI): 384.00 [M+H] + . c) Preparation of methyl 5-(2-amino-4-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)-1H-imidazole-4-carboxylate: methyl 5-bromo-1H-imidazole-4-carboxylate (100 mg, 0.5 mmol) and (2-amino-4-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)boronic acid (187.7 mg, 0.5 mmol) were dissolved in dioxane (10 mL) and water (1 mL), and K2CO3 (258.0 mg, 1.2 mmol) and Pd(dppf)Cl2 (72.6 mg, 0.1 mmol) were added. Stir at 100°C for 18 hours under nitrogen protection. Dilute with water (5 mL) and extract with DCM (10 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by preparative thin layer plate (DCM / MeOH=10 / 1) to obtain the target compound (30 mg, black solid). MS (ESI): 464.20 [M+H] + . d) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one: 5-(2-amino-4-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)-1H-imidazole-4-carboxylic acid methyl ester (30 mg) was dissolved in AcOH (10 mL) and stirred at 80° C. for 3 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure and the crude product was purified by preparative liquid phase (C18, acetonitrile / water, 10-40%, 0.1% formic acid) to give the final product (12.5 mg, white solid, 2-step yield 6%). MS (ESI): 432.20 [M+H] + . 1H NMR (400MHz, DMSO-d6): δ13.52(s,1H),11.52(s,1H),8.43–8.33(m,1H),8.19(s,1H),7.97(s,1H),7.76(d,J=8.1Hz,1H),7.45(d,J=8 .4Hz,1H),7.40(s,1H),7.21(d,J=8.3Hz,1H),3.60(s,2H),2.98–2.87(m,4H),2.76(d,J=4.9Hz,3H),2.61–2.52(m,4H),2.46(s,3H). Embodiment 26 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one a) Preparation of 5-(4-(4-bromo-3-nitrobenzyl)piperazin-1-yl)-N,6-dimethylpicolinamide: 1-Bromo-4-(bromomethyl)-2-nitrobenzene (2.0 g) and N,6-dimethyl-5-(piperazin-1-yl)picolinamide (1.6 g, 6.8 mmol) were dissolved in acetonitrile (30 mL), and KI (113 mg, 0.7 mmol) and DIEA (5.3 g, 40.8 mmol) were added. The reaction solution was stirred at 80°C for 2 hours. Water (50 mL) was added to quench the reaction, and the mixture was extracted with DCM (50 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (PE / EA=10 / 1 to 1 / 1) to obtain the target compound (1.1 g, yellow solid). MS (ESI): 450.30 [M+H] + . b) Preparation of 5-(4-(3-amino-4-bromobenzyl)piperazin-1-yl)-N,6-dimethylpicolinamide: 5-(4-(4-bromo-3-nitrobenzyl)piperazin-1-yl)-N,6-dimethylpicolinamide (1.0 g, 2.1 mmol) was dissolved in EtOH (10 mL) and water (10 mL), and zinc powder (683 mg, 10.5 mmol) and NH4Cl (1.1 g, 21.0 mmol) were added. Stir at room temperature for 16 hours under nitrogen protection. Dilute with water (10 mL) and extract with DCM (10 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM / MeOH=100 / 1 to 20 / 1) to obtain the target compound (470 mg, yellow solid, yield: 50%). MS(ESI):420.05[M+H]+ . c) Preparation of methyl 5-(2-amino-4-(((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)-1-methyl-1H-imidazole-4-carboxylate: methyl 1-methyl-5-(trimethylstannyl)-1H-imidazole-4-carboxylate (220 mg, 0.7 mmol) and 5-(4-(3-amino-4-bromobenzyl)piperazin-1-yl)-N,6-dimethylpicolinamide (302 mg, 0.7 mmol) were dissolved in distilled water. Add oxadiazole (10 mL) and Pd(dppf)Cl2 (73 mg, 0.1 mmol). Stir at 100°C for 16 hours under nitrogen protection. Dilute with water (10 mL) and extract with DCM (10 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by preparative thin layer plate (DCM / MeOH=10 / 1) to obtain the target compound (40 mg, gray solid). MS (ESI): 478.25 [M+H] + . d) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one: 5-(2-amino-4-(((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)-1-methyl-1H-imidazole-4-carboxylic acid methyl ester (40 mg) was dissolved in AcOH (5 mL) and stirred at 80° C. for 3 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure and the crude product was purified by preparative liquid phase (C18, acetonitrile / water, 10-40%, 0.1% formic acid) to give the final product (7.5 mg, white solid, 2-step yield 2%). MS (ESI): 446.15 [M+H] + . 1 H NMR (400MHz, DMSO-d6): δ11.46(s,1H),8.40-8.36(m,1H),8.24(s,1H),8.06(d,J=8.2Hz,1H),7.76(d,J=8.2Hz,1H),7.44(d,J=8Hz,1H),7.42(d ,J=1.6Hz,1H),7.21(dd,J=8.2,1.6Hz,1H),4.12(s,3H),3.60(s,2H),2 .98–2.86(m,4H),2.76(d,J=4.8Hz,3H),2.59–2.50(m,4H),2.46(s,3H). The compounds of Examples 27-29 can be prepared by a synthetic method similar to that of Example 1 (Reaction Scheme 1). The results are shown below. Embodiment 30 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[5,4-c]quinolin-4(5H)-one Ethyl 4-bromoisoxazole-5-carboxylate (45 mg, 0.2 mmol) and (2-amino-4-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)phenyl)boronic acid (64 mg, 0.2 mmol) were dissolved in dioxane (4 mL) and water (1 mL), and K2CO3 (70 mg, 0.5 mmol) and Pd(dppf)Cl2 (15 mg, 0.02 mmol) were added. The mixture was stirred at 100 °C overnight under nitrogen protection. The reaction solution was concentrated, and the crude product was purified by preparative liquid phase to obtain the final product (6.6 mg, gray solid). The compounds of Examples 31-37 and 39 can be prepared by a synthetic method similar to that of Example 1 (Reaction Scheme 1); Example 38 can be prepared by a synthetic method similar to that of Example 40 (Reaction Scheme 4). The results are shown below. Embodiment 40 9-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one a) Preparation of ethyl 3-(2-fluoro-4-(methoxycarbonyl)-6-nitrophenyl)furan-2-carboxylate: Methyl 4-bromo-3-fluoro-5-nitrobenzoate (500 mg, 1.8 mmol), (2-(ethoxycarbonyl)furan-3-yl)boric acid (398.5 mg, 2.1 mmol), Pd(PPh)2Cl2 (126.3 mg, 0.2 mmol) and K2CO3 (496.8 mg, 3.6 mmol) were dissolved in THF (10 mL) and water (2 mL). The reaction solution was stirred at 85°C for 16 hours under nitrogen protection. After the reaction was complete, water (30 mL) was added to quench the reaction and the mixture was extracted with DCM (30 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by preparative thin layer plate (PE:EA=10:1) to obtain the target compound (450 mg, yellow solid, yield: 74%). b) Preparation of 9-fluoro-4-oxo-4,5-dihydrofurano[2,3-c]quinoline-7-carboxylic acid methyl ester: Dissolve 3-(2-fluoro-4-(methoxycarbonyl)-6-nitrophenyl)furan-2-carboxylic acid ethyl ester (450.0 mg, 1.3 mmol) in AcOH (20 mL) and add iron powder (375.2 mg, 6.7 mmol). The reaction solution was stirred at 80°C for 2 hours. After the reaction was complete, the reaction solution was filtered and the filtrate was concentrated under reduced pressure. The obtained product was diluted with water (10 mL) and extracted with DCM (30 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent to obtain the target compound (400 mg, brown solid, crude product). MS (ESI): 262.05 [M+H] + . c) Preparation of 9-fluoro-7-(hydroxymethyl)furo[2,3-c]quinolin-4(5H)-one: 9-fluoro-4-oxo-4,5-dihydrofuro[2,3-c]quinoline-7-carboxylic acid methyl ester (400 mg, crude product) was dissolved in THF (5 mL), and 1M LiAlH4 THF solution (3.1 mL, 3.1 mmol) was added under nitrogen protection at 0°C. The resulting mixture was stirred at 0°C for 20 minutes, and then stirred at room temperature for 2 hours. After the reaction was complete, the reaction was quenched with ice water (20 mL) and the pH was adjusted to 3 with 1M HCl aqueous solution. The resulting aqueous solution was extracted with ethyl acetate (30 mL×3), and the combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent to obtain the target compound (150 mg, yellow solid, 2-step yield: 48%). MS (ESI): 234.00 [M+H] + . d) Preparation of 7-(bromomethyl)-9-fluorofuro[2,3-c]quinolin-4(5H)-one: 9-fluoro-7-(hydroxymethyl)furo[2,3-c]quinolin-4(5H)-one (150 mg, 0.6 mmol) was dissolved in 48% HBr aqueous solution (10 mL) and stirred at 80°C for 2 hours. After the reaction was complete, the reaction solution was concentrated to obtain the target compound (150 mg, yellow solid, crude product). MS (ESI): 297.90 [M+H] + . e) Preparation of 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one: 7-(bromomethyl)-9-fluorofuro[2,3-c]quinolin-4(5H)-one (75.0 mg, crude), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (93.2 mg, 0.4 mmol), KI (16.6 mg, 0.1 mmol) and DIEA (196.7 mg, 1.5 mmol) were dissolved in acetonitrile (10 mL). The reaction solution was stirred at 80° C. for 2 hours. After the reaction was complete, the solvent was removed under reduced pressure, and the crude product was purified by preparative thin layer plate (DCM:MeOH=15:1) to obtain the total product (34.0 mg, white powder, 2-step yield: 16%). The compound of Example 41 can be prepared by a synthetic method similar to that of Example 1 (Reaction Scheme 1); Examples 42 and 45-46 can be prepared by a synthetic method similar to that of Example 7 (Reaction Scheme 3). Examples 43-44 can be prepared by a synthetic method similar to that of Example 6 (Reaction Scheme 2). The results are shown below. Embodiment 47 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one a) Preparation of 7-(hydroxymethyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one: (3-Amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol (500.0 mg, 2.0 mmol), ethyl 5-chloro-3-methyl-3-isoxazole-4-carboxylate (378.0 mg, 2.0 mmol), K2CO3 (553 mg, 4.0 mmol) and Pd(dppf)Cl2 (145 mg, 0.2 mmol) were dissolved in dioxane (5 mL) and the reaction solution was stirred at 100°C overnight under nitrogen protection. After the reaction is complete, add appropriate amount of water to dilute, extract with appropriate amount of ethyl acetate, separate the organic phase, wash with saturated brine, dry with anhydrous Na2SO4, and concentrate to obtain the target compound (350.0 mg, white solid, crude product), which is directly used in the next step without further purification. MS (ESI): 231.05 [M+H] + . b) Preparation of 7-(bromomethyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one: 7-(hydroxymethyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one (350.0 mg, crude product) was dissolved in 48% HBr aqueous solution (6 mL) and stirred at 85°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the obtained product was dissolved in acetonitrile (3 mL). The solvent was removed under reduced pressure to obtain the target compound (150.0 mg, yellow solid, crude product). MS (ESI): 294.95 [M+H] + . c) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one: 7-(bromomethyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one (324.0 mg, crude), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (297.0 mg, 1.0 mmol), KI (45.0 mg) and DIEA (387.0 mg, 3.0 mmol) were dissolved in acetonitrile (6 mL). The reaction mixture was stirred at 80° C. for 4 hours. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by preparative liquid phase separation to obtain the final product (4.2 mg, white solid, 3-step yield: 1%). MS (ESI): 447.25 [M+H] + . 1 H NMR (400MHz, DMSO-d6): δ11.88(s,1H),8.43(d,J=5.3Hz,1H),7.99(d,J=8.1Hz,1H),7.79(d,J=8.3Hz,1H),7.48(d,J=6.8Hz,2 H),7.33(d,J=8.1Hz,1H),3.67(s,2H),2.99–2.93(m,4H),2.80(d,J=4.8Hz,3H),2.64-2.57(m,4H),2.56(s,3H),2.49(s,3H). Embodiment 48 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one a) Preparation of tert-butyl 2-(4-bromo-3-fluoro-2-nitrophenyl)-1H-pyrrole-1-carboxylate: 1,4-dibromo-2-fluoro-3-nitrobenzene (1.0 g, 3.4 mmol), (1-(tert-butyloxycarbonyl)-1H-pyrrole-2-yl)boric acid (745.9 mg, 3.5 mmol), Pd(PPh3)4 (389.2 mg, 0.3 mmol) and Na2CO3 (1.3 g, 11.8 mmol) were dissolved in toluene (20 mL) and water (4 mL). Stirred at 85°C for 16 hours under nitrogen protection. After the reaction was complete, water (50 mL) was added for dilution and extracted with DCM (50 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (EtOAc / PE: 1% to 10%) to obtain the target compound (1.2 g, yellow oil, yield: 92.2%). b) Preparation of 8-bromo-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one: 2-(4-bromo-3-fluoro-2-nitrophenyl)-1H-pyrrole-1-carboxylic acid tert-butyl ester (1.2 g, 3.2 mmol) was dissolved in AcOH (50 mL) and iron powder (905 mg, 16.2 mmol) was added. The reaction solution was stirred at 80°C for 3 hours. After the reaction was complete, the reaction solution was filtered and the filtrate was concentrated under reduced pressure. The obtained product was diluted with water (50 mL) and extracted with DCM (30 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (EtOAc / PE: 5% to 20%) to obtain the target compound (165 mg, yellow solid, yield: 18.9%). MS (ESI): 280.95 [M+H] + . c) Preparation of 7-fluoro-8-(hydroxymethyl)pyrrolo[1,2-c]quinazolin-5(6H)-one: 8-bromo-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one (105 mg, 0.38 mmol), tributyltinmethanol (181 mg, 0.56 mmol) and Xphos PdG2 (44 mg, 0.06 mmol) were dissolved in dioxane (5 mL). The mixture was stirred at 90°C overnight under nitrogen protection. After the reaction was completed, 1M KF aqueous solution (10 mL) was added at room temperature, stirred at room temperature for 30 minutes and then filtered. The filtrate was extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, concentrated under reduced pressure to remove the solvent, and the crude product was purified by silica gel column chromatography (EtOAc / PE: 10% to 50%) to obtain the target compound (65 mg, white solid, yield: 74.9%). MS(ESI):233.00[M+H] + . d) Preparation of 8-(chloromethyl)-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one: Dissolve 7-fluoro-8-(hydroxymethyl)pyrrolo[1,2-c]quinazolin-5(6H)-one (57.0 mg, 0.25 mmol) in DCM (5 mL), add SOCl2 (58.1 mg, 0.49 mmol) and 2 drops of DMF. Stir the reaction mixture at 80°C for 2 hours. Concentrate the reaction mixture to obtain the target compound (55.3 mg, yellow solid, crude product). MS (ESI): 251.00 [M+H] + . e) Preparation of 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one: 8-(Chloromethyl)-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one (20.0 mg crude), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (22.5 mg, 0.10 mmol), KI (1.3 mg, 0.01 mmol) and K2CO3 (44.2 mg, 0.32 mmol) were dissolved in acetonitrile (5 mL). The reaction solution was stirred at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure to remove the reaction solution, and the crude product was purified by preparative thin layer plate (DCM:MeOH=10:1) to give the final product (7.2 mg, white solid, yield: 19.5%). MS(ESI):449.20[M+H] + . 1 H NMR (400MHz, DMSO-d6): δ11.54(s,1H),8.38(d,J=4.5Hz,1H),7.74(d,J=8.2Hz,1H),7.70(d,J=8.1Hz,1H),7.61(s,1H),7.43(d,J=8.3Hz,1H),7 .20(t,J=7.0Hz,1H),7.01(s,1H),6.67(d,J=3.4Hz,1H),3.64(s,2H),2 .93–2.88(m,4H),2.75(d,J=4.4Hz,3H),2.59–2.55(m,4H),2.44(s,3H). Embodiment 49 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one a) Preparation of 4-fluoro-1H-pyrazole-5-carbonyl chloride: Dissolve 4-fluoro-1H-pyrazole-5-carboxylic acid (175.0 mg, 1.35 mmol) in SOCl2 (5 mL), stir at 80°C for 2 hours under nitrogen protection, and concentrate under reduced pressure to obtain the target compound (160 mg, white solid, crude product). b) Preparation of methyl 4-fluoro-3-(4-fluoro-1H-pyrazole-5-carboxamide)benzoate: methyl 3-amino-4-fluorobenzoate (218 mg, 1.3 mmol) was dissolved in THF (3 mL), and LiHMDS (1.0 M THF solution, 3.2 mL) was added under nitrogen protection at 0°C, and stirred at 0°C for 15 minutes. Then a solution of 4-fluoro-1H-pyrazole-5-carbonyl chloride (160.0 mg, 1.1 mmol) in THF (3 mL) was slowly added dropwise. After the reaction was complete, water (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (5 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was purified by preparative thin layer plate (DCM:MeOH=20:1) to obtain the target compound (110 mg, white solid, yield: 36%). MS (ESI): 282.00 [M+H] + . c) Preparation of methyl 3-fluoro-4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carboxylate: Dissolve methyl 4-fluoro-3-(4-fluoro-1H-pyrazole-5-carboxamide)benzoate (100 mg, 0.4 mmol) in DMSO (10 mL), add K2CO3 (194 mg, 1.4 mmol), and stir overnight at 120°C under nitrogen protection. After the reaction is complete, dilute with water (20 mL) and extract with ethyl acetate (10 mL×3). The combined organic phases are washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent to obtain the target compound (85 mg, white solid, yield: 91%). MS (ESI): 262.05 [M+H] + . d) Preparation of 3-fluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one: 3-fluoro-4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carboxylic acid methyl ester (85 mg, 0.33 mmol) was dissolved in THF (3 mL) and water (1 mL), and 1M LiAlH4 solution in THF (1.3 mL) was added under nitrogen protection. The reaction was stirred at 0°C for 10 minutes, then quenched with water (3 mL), 1M NaOH solution (1 mL) was added, and the resulting solution was stirred at room temperature for 15 minutes. The reaction solution was filtered and the filtrate was concentrated under reduced pressure. The crude product was slurried with a mixed solvent of methanol and ethyl acetate (MeOH:EtOAc=2:3) to obtain the target compound (70 mg, white solid, yield: 92%). MS (ESI): 234.00 [M+H] + . e) Preparation of 7-(chloromethyl)-3-fluoropyrazolo[1,5-a]quinoxaline-4(5H)-one: 3-Fluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one (50 mg, 0.22 mmol) was dissolved in DCM (3 mL), and DMF (1.0 mg) and SOCl2 (5 mL) were added at 0°C. The resulting mixture was stirred at 0°C for 10 minutes. The reaction mixture was concentrated to obtain the target compound (54.0 mg, yellow solid, crude product). MS (ESI): 252.20 [M+H] + . f) Preparation of 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one: 7-(Chloromethyl)-3-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (54.0 mg, 0.2 mmol), 6-fluoro-N-methyl-5-(piperazin-1-yl)picolinamide (52 mg, 0.2 mmol), KI (3.6 mg, 0.02 mmol) and DIEA (146.2 mg, 1.1 mmol) were dissolved in acetonitrile (5 mL). The resulting mixture was stirred at 80° C. for 2 hours. After the reaction was completed, water (10 mL) was added to dilute it, and it was extracted with ethyl acetate (5 mL×3). The organic phases were combined and concentrated to remove the solvent. The crude product was purified by preparative thin layer plate (DCM:MeOH=20:1) to obtain the final product (20.8 mg, white solid, yield: 21%). Embodiment 50 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one a) Preparation of 4-amino-7-bromo-8-fluoroquinazolin-2(1H)-one: 2-amino-4-bromo-3-fluorobenzonitrile (800 mg, 3.72 mmol) and chlorosulfonyl isocyanate (632 mg, 4.48 mmol) were dissolved in DCM (5 mL) and stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the resultant was diluted with saturated aqueous NaHCO3 solution (10 mL) and stirred at 100°C for 1 hour. After cooling to room temperature, the mixture was filtered, and the solid was washed with water (10 mL) and dried to obtain the target compound (780 mg, off-white solid, yield: 79%). MS (ESI): 257.96 [M+H] + . b) Preparation of 8-bromo-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one: 4-amino-7-bromo-8-fluoroquinazolin-2(1H)-one (190 mg, 0.74 mmol) and chloroacetaldehyde (287 mg, 3.68 mmol) were dissolved in DMF (5 mL), sodium acetate (151 mg, 1.84 mmol) was added, and stirred at 100°C for 3 hours. After cooling to room temperature, the mixture was filtered, and the solid was washed with water (5 mL) and dried to obtain the target compound (95 mg, gray solid, yield: 46%). MS (ESI): 281.96 [M+H] + . c) Preparation of 7-fluoro-8-(hydroxymethyl)imidazo[1,2-c]quinazolin-5(6H)-one: 8-bromo-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (90 mg, 0.32 mmol), Bu3SnCH2OH (123 mg, 0.38 mmol) and Xphos Pd G2 (25 mg, 0.03 mmol) were dissolved in dioxane (5 mL). The reaction solution was stirred at 90°C overnight under nitrogen protection. After the reaction was complete, 1M KF aqueous solution (5 mL) was added at room temperature, stirred at room temperature for 10 minutes and then filtered. The filtrate was extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4, concentrated under reduced pressure to remove the solvent, and the crude product was slurried with EtOAc:PE=1:1 (50 mL) to obtain the target compound (61 mg, white solid, yield: 81%). MS(ESI):234.06[M+H] + . d) Preparation of 8-(bromomethyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one: 7-fluoro-8-(hydroxymethyl)imidazo[1,2-c]quinazolin-5(6H)-one (90 mg, 0.38 mmol) was dissolved in DCM (5 mL), PBr3 (514 mg, 1.9 mmol) was added at 0°C under nitrogen protection, and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was slurried with DCM (5 mL) to obtain the target compound (65 mg, white solid, yield: 65%). MS (ESI): 295.90 [M+H] + . e) Preparation of 8-((4-(2-methyl-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one: 8-(bromomethyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one (30 mg, 0.17 mmol), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (46.1 mg, 0.18 mmol), KI (3.0 mg, 0.015 mmol) and DIEA (97.1 mg, 0.75 mmol) were dissolved in acetonitrile (10 mL). The reaction mixture was stirred at 80° C. for 2 hours. The reaction mixture was concentrated under reduced pressure and the crude product was purified by preparative thin layer plate (DCM:MeOH=10:1) to give the final product (36.8 mg, white solid, yield: 80%). The compounds of Examples 51-60 can be prepared by a synthetic method similar to that of Example 49 (Reaction Scheme 5); and Examples 61-65 can be prepared by a synthetic method similar to that of Example 50 (Reaction Scheme 6). The results are shown below. Embodiment 66 7-((4-(2-Fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one a) Preparation of ethyl 3-(4-bromo-3-fluoro-2-nitrophenyl)furan-2-carboxylate: Dissolve 1,4-dibromo-2-fluoro-3-nitrobenzene (12.5 g, 42.09 mmol) in DMF (125 mL), add (2-(ethoxycarbonyl)furan-3-yl)boric acid (7.74 g, 42.09 mmol), Pd(dppf)Cl2 dichloroethane complex (3.43 g, 4.21 mmol) and Cs2CO3 (41.2 g, 126.26 mmol). The reaction solution was stirred at 100°C for 3 hours. Water (150 mL) was added to the reaction solution, and extracted with ethyl acetate (100 mL×3). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether containing 0-5% ethyl acetate as mobile phase) to obtain the product (7.16 g, yellow oil, yield: 48%). MS (ESI): 357.90 [M+H] + . b) Preparation of 7-bromo-6-fluorofuran[2,3-c]quinolin-4(5H)-one: Dissolve 3-(4-bromo-3-fluoro-2-nitrophenyl)furan-2-carboxylic acid ethyl ester (5.4 g, 15.08 mmol) in AcOH (100 mL) and add iron powder (4.2 g, 75.39 mmol). The reaction solution was stirred at 80°C for 3 hours. After the reaction was complete, the reaction solution was concentrated and the crude product was purified by silica gel column chromatography (petroleum ether containing 0-5% ethyl acetate as the mobile phase) to obtain the product (3.07 g, yellow solid, yield: 72%). MS (ESI): 281.95 [M+H] + . c) Preparation of 6-fluoro-7-(hydroxymethyl)furan[2,3-c]quinolin-4(5H)-one: 7-bromo-6-fluorofuran[2,3-c]quinolin-4(5H)-one (3.07 g, 10.89 mmol) was dissolved in dioxane (60 mL) at room temperature and (tributyltin)methanol (5.24 g, 16.33 mmol) and Xphos Pd G2 (857.6 mg, 1.09 mmol) were added. The reaction solution was stirred at 100°C for 3 hours. After the reaction was complete, the reaction solution was filtered. The filter cake was washed with DMF, the DMF solution phase was concentrated, and the residue was washed with dichloromethane to obtain the product (1.2 g, white solid, yield: 47%). MS (ESI): 234.05 [M+H] + . d) Preparation of 7-(bromomethyl)-6-fluorofuran[2,3-c]quinolin-4(5H)-one: 6-fluoro-7-(hydroxymethyl)furan[2,3-c]quinolin-4(5H)-one (1.2 g, 5.15 mmol) was dissolved in DCM (50 mL) and phosphorus oxybromide (2.8 g, 10.30 mmol) was added. The reaction solution was stirred at room temperature for 16 hours. After the reaction was complete, the reaction solution was concentrated to obtain the product (1.4 g, crude product, white solid, yield: 92%), which was used directly in the next step without purification. MS (ESI): 295.85 [M+H] + . e) Preparation of 7-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one: 7-(bromomethyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one (52.7 mg, 0.18 mmol), KI (3.0 mg, 0.02 mmol) and N-ethyl-6-fluoro-5-(piperazin-1-yl)picolinamide (45.0 mg, 0.18 mmol) were dissolved in acetonitrile (20 mL), and K2CO3 (73.9 mg, 0.54 mmol) was added at room temperature. The reaction solution was stirred at 80°C for 3 hours. After the reaction was complete, the reaction solution was cooled to room temperature and filtered. The filter cake was purified by preparative HPLC to obtain the target product (35.2 mg, white solid, yield: 42%). Examples 67 and 68 were prepared using a synthetic method similar to Example 66 (reaction scheme 7). Examples 69-71 were prepared using a synthetic method similar to Example 1 (reaction scheme 1). Examples 72 and 73 were prepared using a synthetic method similar to Example 48. Examples 74-87 were prepared using a synthetic method similar to Example 40 (reaction scheme 4). The results are as follows: Embodiment 88 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one a) Preparation of (3-amino-4-bromo-2-fluorophenyl)methanol: (4-bromo-2-fluoro-3-nitrophenyl)methanol (1.6 g, 7.2 mmol) was dissolved in AcOH (25 mL), iron powder (1.2 g, 21.6 mmol) was added at room temperature, and stirred at 85 ° C for 1 hour under nitrogen protection. Dilute with water (50 mL) and extract with ethyl acetate (50 mL × 2). The organic phases were combined, washed with saturated NaHCO3 solution and saturated brine in turn, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The crude product was slurried with PE / EA (v / v = 20 / 1, 10 mL) to obtain the target compound (900 mg, orange solid, yield: 56%). MS (ESI): 219.90 [M+H] + . b) Preparation of (3-amino-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol: (3-amino-4-bromo-2-fluorophenyl)methanol (730 mg, 3.3 mmol), bipyraclostrobin (1.1 g, 4.0 mmol), KOAc (980 mg, 10.0 mmol) and Pd(dppf)Cl2 (239 mg, 0.3 mmol) were dissolved in dioxane (10 mL) and stirred at 100°C overnight under nitrogen protection. Dilute with water (50 mL) and extract with ethyl acetate (50 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (PE / EA=3 / 1) to obtain the target compound (0.6 g, yellow solid, yield: 68%). MS (ESI): 267.85 [M+H] + . c) Preparation of methyl 3-(2-amino-3-fluoro-4-(hydroxymethyl)phenyl)-1-methyl-1H-pyrazole-4-carboxylate: (3-amino-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol (0.4 g, 1.4 mmol), methyl 3-bromo-1-methyl-1H-pyrazole-4-carboxylate (284 mg, 1.4 mmol), K2CO3 (0.6 g, 4.2 mmol) and Pd(dppf)Cl2 (80 mg, 0.1 mmol) were dissolved in dioxane (5 mL) and water (1 mL), and stirred at 100°C overnight under nitrogen protection. The reaction solution was filtered and the filtrate was concentrated under reduced pressure to obtain the crude target compound (0.4 g, brown solid). d) Preparation of 6-fluoro-7-(hydroxymethyl)-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: A solution of methyl 3-(2-amino-3-fluoro-4-(hydroxymethyl)phenyl)-1-methyl-1H-pyrazole-4-carboxylate (0.4 g, 1.4 mmol) in AcOH (5 mL) was stirred at room temperature for 2 hours. The reaction solution was then concentrated under reduced pressure, and the crude product was slurried three times with a mixed solvent of petroleum ether and ethyl acetate (PE:EA=1:1, 5 mL) to obtain the target product (0.4 g, brown solid). MS (ESI): 248.00 [M+H] + . e) Preparation of 7-(bromomethyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: A mixture of 6-fluoro-7-(hydroxymethyl)-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one and HBr (48% aqueous solution, 18 mL) was stirred at 85°C for 1 hour. The reaction solution was then concentrated under reduced pressure to give the target crude product (0.4 g, brown solid). MS (ESI): 309.90 [M+H] + . f) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one: 7-(bromomethyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one (100 mg, 0.4 mmol), 6-fluoro-N-methyl-5-(piperazin-1-yl)picolinamide (165 mg, 1.3 mmol), KI (7.0 mg, 0.04 mmol) and DIEA (81 mg, 0.6 mmol) were dissolved in acetonitrile (10 mL). The reaction mixture was stirred at 80° C. for 2 hours. The reaction mixture was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (10.0 mg, white solid, 4-step yield: 5.0%). Examples 89-100 were prepared by a synthetic method similar to Example 1 (reaction scheme 1). Examples 101-118 were prepared by a synthetic method similar to Example 66 (reaction scheme 7). Examples 119-120 were prepared by a synthetic method similar to Example 48. The results are as follows: Embodiment 121 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one a) Preparation of 4-fluoro-1H-pyrazole-5-carboxylic acid chloride: 4-fluoro-1H-pyrazole-5-carboxylic acid (1.1 g, 8.5 mmol) was dissolved in SOCl2 (12 mL) and stirred at 80°C for 2 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure to obtain the product (1.0 g, white solid, yield: 83%). b) Preparation of N-(3-bromo-2,6-difluorophenyl)-4-fluoro-1H-pyrazole-5-carboxamide: 3-bromo-2,6-difluoroaniline (1.5 g, 7.4 mmol) was dissolved in THF (15 mL), and LiHMDS (1M THF solution, 20.2 mL, 20.2 mmol) was added under nitrogen protection at 0°C. The reaction solution was stirred at 0°C for 30 minutes, and a THF (10 mL) solution of 4-fluoro-1H-pyrazole-5-carbonyl chloride (1.0 g, 6.7 mmol) was added dropwise. After the reaction solution was stirred at 0°C for 30 minutes, it was stirred at room temperature for another 1.5 hours. Water (20 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE / EA=5 / 1) to obtain the product (1.5 g, yellow solid, yield: 72%). MS:319.95[M+H] + ,321.95[M+H+2] + . c) Preparation of 7-bromo-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one: N-(3-bromo-2,6-difluorophenyl)-4-fluoro-1H-pyrazole-5-carboxamide (1.5 g, 4.7 mmol) was dissolved in DMSO (15 mL) and K2CO3 (2.6 g, 18.7 mmol) was added under nitrogen protection. The reaction solution was stirred at 100°C overnight. The reaction solution was cooled to room temperature. Water (20 mL) was added to quench the mixture and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by preparative column (C18, water / acetonitrile=55 / 45) to obtain a white solid product, which was used directly in the next step without further purification. MS(ESI):300.00[M+H] + ,302.00[M+H+2] + . d) Preparation of 3,6-difluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one: 7-bromo-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one (1.2 g, 4.0 mmol) was dissolved in dioxane (12 mL), and Xphos Pd G2 (314.7 mg, 0.4 mmol) and (tributyltin)methanol (3.9 g, 12 mmol) were added under nitrogen protection. The reaction solution was stirred at 80°C for 4 hours. The reaction solution was cooled to room temperature and KF aqueous solution (1 M, 24 mL) was added. The mixture was filtered and the filtrate was extracted with ethyl acetate (20 mL×3). The organic phase was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM / MeOH=1 / 0-100 / 1-80 / 1-50 / 1) to obtain the product (260.0 mg, white solid, 2-step yield: 22%). MS (ESI): 252.10 [M+H] + . 1 H NMR (400MHz, DMSO-d6): δ 11.94 (s, 1H), 8.20 (d, J = 3.8Hz, 1H), 7.89 (d, J = 8.6Hz, 1H), 7.36 (t, J = 7.7Hz, 1H), 5.44 (t, J = 5.8Hz, 1H), 4.61 (d, J = 5.5Hz, 2H). e) Preparation of 7-(bromomethyl)-3,6-difluoropyrazolo[1,5-a]quinoxaline-4(5H)-one: 3,6-difluoro-7-(hydroxymethyl)pyrazolo[1,5-a]quinoxaline-4(5H)-one (200.0 mg, 0.8 mmol) was dissolved in 48% HBr aqueous solution (20 mL) and stirred at 80°C under nitrogen protection for 2 hours. The product was concentrated under reduced pressure to obtain the product (261.0 mg, white solid, yield: 96%). MS (ESI): 313.95 [M+H] + ,315.95[M+H+2] + . f) Preparation of 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one: 7-(bromomethyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (53.0 mg, 0.2 mmol) was dissolved in acetonitrile (5 mL), and KI (3.4 mg, 0.02 mmol), N,6-dimethyl-5-(piperazin-1-yl)picolinamide (47.0 mg, 0.2 mmol) and DIEA (129.0 mg, 1.0 mmol) were added under nitrogen protection at room temperature. The mixture was stirred at 80°C for 4 hours. The reaction solution was concentrated and the residue was purified by preparative thin layer plate (DCM / MeOH=10 / 1). The crude product was purified by preparative high performance liquid chromatography (water / acetonitrile=42 / 58%, 0.1% formic acid) to give the product (48.8 mg, white solid, yield: 62%). Examples 121-128 were prepared using a synthetic method similar to Example 121 (Reaction Scheme 8). Embodiment 129 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one a) Preparation of (4-bromo-3-fluoro-2-nitrophenyl)hydrazine: 4-bromo-3-fluoro-2-nitroaniline (5.0 g, 21.3 mmol) was dissolved in concentrated hydrochloric acid (36% aqueous solution, 50 mL), and a solution of NaNO2 (14.4 g, 64.0 mmol) in water (50 mL) was added dropwise at -10°C, and the reaction solution was stirred at -10°C for 1 hour. The reaction solution was cooled to -30°C, and a solution of SnCl2·2H2O (1.6 g, 23.4 mmol) in concentrated hydrochloric acid (36% aqueous solution, 50 mL) was added, and the reaction solution was stirred at -30°C for 1 hour. After the reaction was complete, the reaction solution was poured into ice water (200 mL), and the pH was adjusted to 7-8 with solid NaHCO3. The mixed solution was extracted with ethyl acetate (100 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product (4.3 g, yellow solid, yield: 81%). b) Preparation of 1-(4-bromo-3-fluoro-2-nitrophenyl)-4-methyl-1H-pyrazole-5-carboxylic acid methyl ester: (4-bromo-3-fluoro-2-nitrophenyl) hydrazine (1.0 g, 4.0 mmol) was dissolved in acetic acid (10 mL), and a solution of 4-(dimethylamino)-3-methyl-2-oxobut-3-enoic acid methyl ester (0.82 g, 4.8 mmol) in acetic acid (10 mL) was added at room temperature. The reaction solution was stirred at 80°C overnight. After the reaction was complete, the reaction solution was poured into ice water (100 mL) and extracted with ethyl acetate (100 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA=15:1) to obtain the product (0.83 g, yellow solid, yield: 58%). 1 H NMR (400MHz, DMSO-d6): δ8.16-8.14(m,1H),7.78(s,1H),7.61-7.59(m,1H),3.71(s,3H),2.25(s,3H). c) Preparation of 7-bromo-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one: 1-(4-bromo-3-fluoro-2-nitrophenyl)-4-methyl-1H-pyrazole-5-carboxylic acid methyl ester (0.83 g, 2.3 mmol) was dissolved in acetic acid (10 mL), and iron powder (0.65 g, 11.6 mmol) was added at room temperature. The reaction solution was stirred at 80°C overnight. After the reaction was complete, the reaction solution was filtered, and the filtrate was diluted with water (5 mL) and ethyl acetate (5 mL), and the product (370 mg, off-white solid, yield: 55%) was obtained by filtration. MS (ESI): 295.90 [M+H] + ,293.85[MH] - . 1 H NMR (400MHz, DMSO-d6): δ11.90(br,1H),7.91(s,1H),7.77(d,J=8.0Hz,1H),7.50-7.46(m,1H),2.38(s,3H). d) Preparation of 6-fluoro-7-(hydroxymethyl)-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one: 7-bromo-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one (5.0 g, 16.9 mmol) was dissolved in dioxane (100 mL), and (tributyltin)methanol (10.9 g, 33.9 mmol) and Xphos Pd G2 (1.3 g, 1.7 mmol) were added at room temperature. The reaction solution was stirred at 90°C under nitrogen protection for 16 hours. After the reaction was complete, KF solution (1M, 100 mL) was added at room temperature. The mixed solution was stirred at room temperature for 10 minutes and filtered. The filtrate was extracted with ethyl acetate (200 mL×3). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was slurried with a PE / EA (v / v=1:1) mixture to obtain the product (2.8 g, gray solid, yield: 67%). MS (ESI): 248.05 [M+H] + ,246.00[MH]-. e) Preparation of 7-(bromomethyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one: 6-fluoro-7-(hydroxymethyl)-3-methylpyrazolo[1,5-a]quinoxaline-4(5H)-one (2.8 g, 11.3 mmol) was dissolved in 48% HBr aqueous solution (30 mL), and the reaction solution was stirred at 80°C for 2 hours. After the reaction was complete, the product was concentrated under reduced pressure to obtain a crude product (2.7 g, yellow solid). MS (ESI): 309.90 [M+H] + ,311.90[M+H+2] + . f) Preparation of 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one: 7-(bromomethyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one (193.8 mg crude product, 0.63 mmol), KI (8.7 mg, 0.05 mmol), N-(2,2-difluoroethyl)-6-fluoro-5-(piperazin-1-yl)picolinamide (150.0 mg, 0.52 mmol) and K2CO3 (359.5 mg, 2.61 mmol) were dissolved in CH3CN (20 mL) at room temperature. The reaction solution was stirred at 80°C for 3 hours. After the reaction was complete, the reaction solution was filtered. The crude product was purified by preparative HPLC (C18, acetonitrile / water 5-50%, 0.1% formic acid) to give the title compound (21.8 mg, white solid, yield: 8.1%). Examples 130-135, 151-167 and 203-204 were prepared by a synthetic method similar to Example 129 (reaction scheme 9). Examples 136-141 were prepared by a synthetic method similar to Example 50 (reaction scheme 6). Examples 142-144 and 149 were prepared by a synthetic method similar to Example 1 (reaction scheme 1). Example 145 was prepared by a synthetic method similar to Example 49 (reaction scheme 5). Examples 146-148 were prepared by a synthetic method similar to Example 66 (reaction scheme 7). Example 150 was prepared by a synthetic method similar to Example 6 (reaction scheme 2). Examples 168-202 were prepared by a synthetic method similar to Example 121 (reaction scheme 8). Example 205 was prepared by a synthetic method similar to Example 48. Embodiment 206 The inhibitory effect of the compounds of the present invention on PARP1 and PARP2 enzyme activities was determined by chemiluminescence detection The dilution solution (40 ng enzyme / well) of recombinant poly ADP ribosyltransferase 1 and 2 (PARP1 and PARP2) and the test compound were added to a 96-well plate coated with recombinant protein and incubated at room temperature for 1 hour, then 50 μL of 0.3 ng / mL horseradish peroxidase streptavidin (Streptavidin-HRP) was added to each well and incubated at room temperature for 30 minutes. Finally, the corresponding substrate was added and the plate was read with an EnviSion instrument, the chemiluminescent signal was recorded, and the inhibition rate of the test compound on the enzyme activity of PAPP1 and PARP2 was calculated according to the following formula. Note: The reading of the negative control well is the reading of the well with only enzyme diluent (no enzyme and test compound), indicating 0% enzyme activity; the reading of the positive control well is the reading of the well with 1% DMSO (no test compound), indicating 100% enzyme activity; X is the reading of the well with the test compound. Table 1 summarizes the inhibitory effects (IC 50 ). Table 1 Most compounds showed potent and selective inhibition of the PARP1 enzyme relative to PARP2. Embodiment 207 Inhibitory effect of the compounds of the present invention on the growth of BRCA mutant human breast cancer cell MDA-MB-436 After cell recovery, complete medium (DMEM medium + 10% FBS + insulin + glutathione) was used for culture and passage. When the cell confluence reaches about 80%, use a 1mL pipette to gently blow the cells off from the bottom of the culture dish, collect the cell suspension, and centrifuge at 500rpm for 3min; discard the supernatant, add complete medium to resuspend the cells, inoculate them into the culture dish according to the appropriate proportion, and place them in a 37°C, 5% CO2 incubator for static culture. The cells were cultured and passaged until they were in good growth state and the confluence was about 80%, and then they were used for experiments. Use a 1mL pipette to gently blow off the cells in the logarithmic growth phase, centrifuge at 500rpm for 3min, discard the supernatant, resuspend them with fresh medium, disperse them into single cells, count them, and inoculate them into a 96-well cell culture plate (the first column is empty) at a density of 3000 cells per well, and place them in a 37°C, 5% CO2 incubator for overnight culture. The next day, the compound stock solution was serially diluted with DMSO at a ratio of 1:3 for a total of 8 concentrations. 5 μL of each concentration was added to 120 μL of culture medium (25-fold dilution). At the same time, a DMSO control well (DMSO concentration of 0.1%) was made and shaken to mix. The cells were removed from the CO2 incubator, the old culture medium in the well was discarded, 195 μL of fresh culture medium was added to each well, and then 5 μL of the compound containing the corresponding concentration diluted in the culture medium was added to the corresponding wells. The culture plate was then placed in a 37°C 5% CO2 incubator for a total of 7 days, with the drug changed once on the 4th day. After 7 days, 20 μL of CCK-8 was added to each well and shaken, and the culture was continued. After 4 hours, shake for 5 minutes and place on a multi-function reader to read the absorbance value at a wavelength of 450nm or 650nm (OD value = absorbance value 450nm -Absorbance 650nm ). The data were analyzed using GraphPad Prism 6.0 software, and the inhibitory activity of the compounds on cell proliferation was plotted using cell survival rate and compound concentration as coordinates. Cell survival rate % = (OD 化合物 -OD 背景 ) / (OD DMSO -OD 背景 )×100. IC 50 The values were fitted with an S-shaped dose-response curve equation: Y = 100 / (1+10^(LogC-LogIC50 )), C is the concentration of the compound. Table 2 summarizes the inhibitory effect of the compounds on the growth of human breast cancer cells MDA-MB-436 (IC 50 ). Table 2 The compound of the present invention has a good inhibitory effect on the growth of BRCA mutated MDA-MB-436 cells. Embodiment 208 Inhibitory effect of the compounds of the present invention on PDE3A The PDE3A fluorescence polarization (FP) method was used to detect the inhibitory effect of the compounds of the present invention on PDE3A. The PDE3A FP assay is a multi-step reaction performed in a black round bottom 384-well plate (Corning, #4514). First, a 10 mM DMSO stock solution of the compound was serially diluted with DMSO at a ratio of 1:3 for a total of 11 concentrations. 50 nL of each concentration was transferred to 5 μL of reaction buffer (10 mM Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 0.2 μM FAM-cAMP (BPS, 60200) and 2 nM PDE3A enzyme (Sino Biological, 1198-H20b1). A DMSO control well (DMSO concentration of 1%) was also prepared and incubated at 25°C for 60 min. Then 15 μL of detection solution (Molecular Devices, R8124) was added and incubated at 25°C for 60 min. Load the plate onto the BMG PHERAstar FSX and read the fluorescence polarization (FP) value with the following settings: Ex: 485nm and Em: 520nm. Record the emission intensity parallel to the polarizer (Em || ) and the emission intensity perpendicular to the polarizer (Em ⊥ ). Using the formula: Calculate the mP value. Data processing: 1) Calculate the inhibition rate of each concentration point of the compound %Inh = (mP max -mP 化合物 ) / (mP max -mP min )×100%, where mP Min and mP Max Polarization readouts for substrate only and substrate + enzyme conditions, respectively. 2) The IC was calculated by nonlinear fitting using the commercial fitting software GraphPad Prism 9.2.0 using the following regression equation: 50 Value: Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)×Hillslope)), where X represents the Log value of the compound concentration and Y represents the %Inh of each concentration point of the compound. Table 3 summarizes the inhibitory effect data of the compounds of the present invention on PDE3A (IC 50 ). Table 3 The compounds of the present invention have low inhibitory effects on PDE3A, and some compounds have inhibitory effects of IC 50 >30μM.
[0195] Although the present invention has been fully described, it will be appreciated by those skilled in the art that the same implementation can be performed in a wide range of and equivalent conditions, formulations and other parameter ranges without affecting the scope of the present invention or any embodiment thereof. All patents, patent applications and publications cited herein are incorporated herein by reference in their entirety.
Claims
1. A compound represented by the following formula I, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof: in, A 1 , A 2 and A 3 Each independently selected from N and CR 1 ; The Z ring is as follows The optionally substituted 5-membered heteroaryl, the optionally substituted 5-membered carbocyclic group or the optionally substituted 5-membered heterocyclic group shown in the figure, * represents the position where the Z ring is connected to the rest of the compound, and the dotted line represents the optional presence of an unsaturated bond, wherein when the Z ring is an optionally substituted 5-membered heteroaryl, Z 1 , Z 2 and Z 3 Each is independent of CR 2 NR 3 , O, N or S, Z 4 and Z 5 are independently C or N, and Z 4 and Z 5 are not N at the same time; when Z ring is an optionally substituted 5-membered carbocyclic group or an optionally substituted 5-membered heterocyclic group, Z 1 , Z 2 and Z 3 Each is independent of CR 2 R 2 ',CR 2 NR 3 , O or S, Z 4 and Z 5 Each is independently C, CH or N; And satisfy: when Z 5 When N, Z 1 , Z 2 and Z 3 At least one of them is N; or when Z 5 is N, and Z 1 -Z 3 CR 2 or CR 2 R 2 ', A 1 CR 1 ; L is selected from a bond and optionally R 4 and / or R 5 substituted alkylene; Cy is selected from optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl; R 1 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy and optionally substituted carbocyclyl; R 2 and R 2 ' are each independently selected from hydrogen, hydroxy, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted alkenyl, and optionally substituted alkynyl; R 3 is selected from hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; R 4 and R 5 are each independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted alkenyl, and optionally substituted alkynyl; or R 4 and R 5 Form a ring with the connected C.
2. The compound according to claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, in, R 1 is hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy; preferably, R 1 is hydrogen, halogen or C 1-3 Alkyl; preferably, A 1 and A 3 At least one of them is CR 1 , and R 1 is a halogen, such as fluorine; or 2 and A 3 At least one is CR 1 , and R 1 is a halogen; or 2 and A 3 All CR 1 , and at least one R 1 is a halogen; or 3 Yes CR 1 , and R 1 is a halogen; or 1 , A 2 and A 3 All CR 1 , R 1 are independently hydrogen, halogen or C 1-3 Alkyl; or A 1 and A 3 At least one of them is CR 1 , where R 1 is halogen, preferably at least A 3 CR 1 , and R 1 is a halogen, such as fluorine; or 1 CR 1 , A 2 and A 3 is CH; or A 1 For CH, A 2 CR 1 , A 3 is CH; or A 1 and A 2 All are CH, A 3 CR 1 , where R 1 Halogen or C 1-3 Alkyl; and / or The Z ring is selected from the following groups: Preferably selected from: More preferably selected from: Wherein, * indicates the position where the Z ring is connected to the rest of the compound; R 2 is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably selected from hydrogen, halogen and optionally substituted C 1-3 Alkyl; R 2 ' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably selected from hydrogen, halogen and optionally substituted C 1-3 Alkyl; R 3 is selected from hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl, preferably hydrogen or optionally substituted C 1-3 Alkyl; and / or L is C 1-3 Alkylene; and / or Cy is optionally substituted by 1 to 5 atoms selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 alkoxy, optionally substituted 6-14 membered aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 4-10 membered heterocyclyl and optionally substituted C 3-8 The 5-7 membered nitrogen-containing heterocyclic group substituted by the cycloalkyl substituent, wherein the 6-14 membered aryl group, the 5-10 membered heteroaryl group, the 4-10 membered heterocyclic group and the C 3-8 The cycloalkyl groups are each optionally substituted by 1 to 5 groups selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, -NR'R", -C(O)-NR'R" and carboxyl, wherein R' and R" are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably R′ and R″ are each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-8 cycloalkyl or an optionally substituted 3-6 membered heterocyclic group; preferably, the 6-14 membered aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclic group and C 3-8 The substituents on the cycloalkyl group include at least -C(O)-NR'R", and optionally further include halogen, C 1-4 Alkyl and halogenated C 1-4 Any one or two of the alkyl groups; Preferably, Cy is substituted by an optionally substituted 5-10 membered heteroaryl, preferably by an optionally substituted 5-10 membered nitrogen-containing heteroaryl, preferably, the 5-10 membered heteroaryl or 5-10 membered nitrogen-containing heteroaryl is at least substituted by said -C(O)-NR′R″, and optionally further substituted by halogen, C 1-4 Alkyl and halogenated C 1-4 Any one or two of the alkyl groups are substituted, and further preferably, the -C(O)-NR′R″ is located at the para position; Preferably, Cy is piperazinyl or dihydropyridinyl substituted by an optionally substituted pyridinyl, and said pyridinyl is substituted by at least said -C(O)-NR'R"; and preferably, Cy is covalently linked to L via its ring nitrogen atom.
3. A compound as claimed in any one of claims 1 to 2, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has a structure shown in the following formula Ia, Ib, Ic or Id: Among them, A 1 , A 2 , A 3 , Z ring, L and Cy as described in any one of claims 1-2; or The compound of formula I has a structure shown in the following formula IIa, IIb, IIc or IId: Among them, A 1 , A 2 , A 3 and Z ring as described in claims 1-2; R 6 is selected from optionally substituted aryl and optionally substituted heteroaryl.
4. The compound according to claim 3, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, in, R 6 is an optionally substituted 6-14 membered aryl or an optionally substituted 5-10 membered heteroaryl, wherein the 6-14 membered aryl and the 5-10 membered heteroaryl are each optionally substituted by 1-5 members selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, -NR'R", -C(O)-NR'R" and carboxyl, wherein R' and R" are each independently hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably R′ and R″ are each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 cycloalkyl or optionally substituted 3-6 membered heterocyclic group; preferably, R 6 The substituents include at least the -C(O)-NR′R″, and optionally further include halogen, C 1-4 Alkyl and halogenated C 1-4 Any one or two of the alkyl groups; preferably, R 6 is a substituted 5-10 membered heteroaryl, preferably a substituted 5-10 membered nitrogen-containing heteroaryl, preferably, the 5-10 membered heteroaryl or 5-10 membered nitrogen-containing heteroaryl is at least substituted by said -C(O)-NR′R″, and optionally further substituted by halogen, C 1-4 Alkyl and halogenated C 1-4 Any one or two of the alkyl groups are substituted; Preferably, R 6 For the following groups: Among them, B 1 , B 2 , B 3 and B 4 Each independently selected from N and CR 7 ; R 7 R' and R" are each independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted carbocyclyl, optionally substituted alkenyl, and optionally substituted alkynyl; 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, preferably R' and R" are each independently H, optionally substituted C 1-4 Alkyl or optionally substituted C 3-6 Cycloalkyl; * indicates the position where the group is connected to the rest of the compound; preferably, containing B 1 , B 2 , B 3 and B 4 The group is phenyl, pyridyl, pyrimidinyl or pyridazinyl; preferably, R 7 H, halogen, C 1-3 Alkyl, C 1-3 Alkoxy or halogenated C 1-3 Alkyl; preferably, B 3 N, B 4 CR 7 , B 1 and B 2 is CH, where R 7 H, halogen, C 1-3 Alkyl, C 1-3 Alkoxy or halogenated C 1-3 Alkyl; R' is hydrogen, R" is hydrogen, C 1-3 Alkyl, deuterated C 1-3 Alkyl, C 3-6 Cycloalkyl or halogenated C 1-3 alkyl.
5. The compound according to claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has a structure shown in the following formula IIIa, IIIb, IIIc or IIId: Among them, Z ring, A 1 , A 2 and A 3 As claimed in any one of claims 1 to 2; B 1 , B 2 , B 3 , B 4 , R′ and R″ as described in claim 4.
6. The compound according to claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has a structure shown in the following formula IVa, IVb, IVc or IVd: Wherein, the Z ring is as described in claim 1 or 2, and R″ is as described in claim 2 or 4; R 7 As claimed in claim 4; R 8 , R 9 and R 10 are each independently selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, and optionally substituted carbocyclyl; Preferably, R 8 , R 9 and R 10 are independently hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy; preferably, R 8 , R 9 and R 10 are independently hydrogen, halogen or C 1-3 Alkyl; preferably, R 8 Halogen or C 1-3 Alkyl, R 9 and R 10 All are CH, or R 8 H, R 9 Halogen or C 1-3 Alkyl, R 10 CH, or R 8 and R 9 Both CH and R 10 Halogen or C 1-3 alkyl; Preferably, R 9 and R 10 At least one of them is a halogen.
7. The compound according to claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has a structure shown in the following formula Va, Vb, Vc or Vd: Among them, Z 1 , Z 2 and Z 3 As claimed in any one of claims 1 to 2; R 8 , R 9 and R 10 As described in claim 6 above; 1 , B 2 , B 3 and B 4 As claimed in claim 4; Ring D is an optionally substituted 4- to 12-membered N-containing heterocyclic group; the N-containing heterocyclic group is selected from a 4-12-membered monocyclic group or a 5-12-membered spirocyclic group containing at least one N atom, and the N-containing heterocyclic group may further include 1-4 heteroatoms selected from N, O or S, and may be optionally further substituted by one or more R"'; W is a bond, O or -NR'-; Q is optionally substituted aminoacyl (-C(O)-NR'R") or optionally substituted heteroaryl; R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R'' is selected from halogen, hydroxy, cyano or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally further substituted by one or more substituents selected from hydroxy, halogen or cyano; or, any two R''s may form a 3-8 membered ring.
8. The compound according to claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has a structure shown in the following formula VIa, VIb or VIc: Among them, Z 1 , Z 2 and Z 3 As claimed in any one of claims 1 to 2; R 7 and Q as claimed in claim 7; R7' is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl; R 9 and R 10 are independently hydrogen, halogen, optionally substituted C 1-3 Alkyl, or optionally substituted C 1-3 Alkoxy, and R 9 and R 10 At least one of them is not hydrogen; D 1 N or CR 11 ; R 11 is H, halogen, cyano, hydroxyl, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy.
9. The compound according to any one of claims 6 to 8, in, The Z ring is: Among them, R 2 is selected from hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; R 2 ' is selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl or C 3-6 Cycloalkyl; and R 2 and R 2 ' is at least one non-hydrogen substituent, preferably, the non-hydrogen substituent is halogen, cyano, C 1-3 Alkyl or C 3-6 Cycloalkyl; and in formula IVa-IVd and Va-Vd, R 8 , R 9 and R 10 Any one of them is halogen or C 1-3 alkyl, and the rest are H. In formula VIa-VId, R 9 and R 10 One of them is halogen or C 1-3 alkyl, the other is H; or The Z ring is: Among them, R 2 ' is selected from halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, preferably halogen, cyano, optionally substituted C 1-3 Alkyl and optionally substituted C 3-6 Cycloalkyl; in formula IVa-IVd and Va-Vd, R 8 For H, R 9 and R 10 Any one of them is halogen or C 1-3 alkyl, the other is H, in Formulas VIa-VId, R 9 and R 10 One of them is halogen or C 1-3 Alkyl and the other is H.
10. The compound according to claim 8, It is characterized in that In Formula VIa, Z 1 , Z 2 and Z 3 One is O and the other two are CR 1 , where R 1 Selected from H, halogen and C 1-3 Alkyl; preferably, Z 1 For O, Z 2 and Z 3 is CH; preferably, R 9 is a non-hydrogen substituent, such as halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; preferably, R 10 is H, halogen or C 1-3 Alkyl, preferably H; D 1 N or CH; R 7 H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H or halogen; preferably, Q is said -C(O)-NR'R" or optionally substituted by 1 or 2 halogens and C 1-3 Alkyl-substituted pyrrolyl, pyrazolyl, imidazolyl or triazolyl, wherein R′ and R″ are each independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group; or In Formula VIa, Z 1 , Z 2 and Z 3 One is O and the other two are CR 1 , preferably, Z 1 For O, Z 2 and Z 3 All are CH; R 1 Selected from H, halogen and C 1-3 Alkyl; R 10 is a non-hydrogen substituent, such as halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy, preferably halogen, more preferably F; R 9 is H, halogen or C 1-3 Alkyl, preferably H; D 1 N or CH; R 7 H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H, halogen, halogenated C 1-3 Alkyl or C 1-3 Alkyl; R 7 ' is H, C 1-3 Alkyl, halogenated C 1-3 Alkyl, halogen, cyano or C 3-6 Cycloalkyl, preferably H or halogen; Q is said -C(O)-NR'R" or optionally substituted by 1 or 2 halogen and C 1-3 Alkyl-substituted pyrrolyl, pyrazolyl, imidazolyl or triazolyl, wherein R′ and R″ are each independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group; preferably, R is not included in Formula VIa 9 H, R 10 For F, R 7 Methyl, D 1 N, R 7 ' is H, Q is -C(O)-NH(CH 3 ) or -C(O)-NH(CD 3 ) and R 9 H, R 10 For F, R 7 F, D 1 N, R 7 ' is H, Q is -C(O)-NH(CH 3 ) or -C(O)-NH(CD 3 ) compounds.
11. The compound according to claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has the structure shown in the following formula VII: Among them, R 9 and R 10 As claimed in claim 8; L and Cy as claimed in any one of claims 1-3; R 12 and R 13 are independently selected from hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl, and R 12 and R 13 At least one of them is not hydrogen.
12. The compound of claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has the structure shown in the following formula VIII: Among them, R 9 and R 10 As claimed in claims 8 and 12; R 12 and R 13 As claimed in claim 12; Ring D and Q as claimed in any one of claims 7 and 8; R 7 As claimed in any one of claims 6 and 8.
13. The compound of claim 11, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, in, R 12 and R 13 are independently hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl; preferably, R 12 is hydrogen, R 13 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 More preferably, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl, R 13 is hydrogen; preferably, R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Cycloalkyl, R 13 is hydrogen; more preferably, R 12 Halogen, C 1-3 Alkyl, halogenated C 1-3 Alkyl; R 13 It is hydrogen; R 9 is hydrogen, R 10 Is halogen or C 1-3 Alkyl; R 9 Is halogen or C 1-3 Alkyl, R 10 is hydrogen; more preferably, R 9 is hydrogen, R 10 is a halogen; or R 9 is a halogen, R 10 It is hydrogen; Ring D is an optionally substituted 4-7 membered monocyclic ring containing at least one N atom; preferably, ring D is an optionally substituted piperazinyl, an optionally substituted piperidinyl or an optionally substituted dihydropyridinyl. When ring D is substituted, the number of substituents may be 1-3 and may be selected from halogen, hydroxyl, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl; R 7 is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, preferably, R 7 is hydrogen, halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl or C 3-6 Cycloalkyl; Q is -C(O)-NR'R", wherein R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Cycloalkyl or an optionally substituted 3-6 membered heterocyclic group; Q is optionally substituted by 1-3 groups selected from halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy and halogenated C 1-3 The substituent of the alkoxy group is a 5-membered heteroaryl group substituted with a pyrrolyl group, a pyrazolyl group, an imidazolyl group or a triazolyl group.
14. The compound of claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that The compound of formula I has the structure shown in the following formula IX: wherein ring D and Q are as described in any one of claims 7 and 8; R 7 As claimed in any one of claims 6 and 8; R 10 is halogen, optionally substituted C 1-3 Alkyl or optionally substituted C 1-3 Alkoxy; R 12 is halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl.
15. The compound of claim 14, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof, It is characterized in that R 10 Halogen or C 1-3 Preferably, R 10 is halogen, preferably F; R 12 is halogen, cyano, optionally substituted C 1-3 Alkyl or optionally substituted C 3-6 Preferably, R 12 Halogen, C 1-3 Alkyl or halogenated C 1-3 alkyl; Ring D is an optionally substituted 4-7 membered monocyclic ring containing at least one N atom; preferably, ring D is an optionally substituted piperazinyl, an optionally substituted piperidinyl or an optionally substituted dihydropyridinyl. When ring D is substituted, the number of substituents may be 1-3 and may be selected from halogen, hydroxyl, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy and optionally substituted C 3-6 Cycloalkyl; or Ring D is selected from the following groups: Preferably, ring D is Wherein, *1 indicates the connection position between ring D and methylene; *2 indicates the connection position between ring D and pyridyl; R 7 is hydrogen, halogen, cyano, optionally substituted C 1-3 Alkyl, optionally substituted C 1-3 Alkoxy or optionally substituted C 3-6 Cycloalkyl, preferably, R 7 is hydrogen, halogen, cyano, C 1-3 Alkyl, halogenated C 1-3 Alkyl or C 3-6 Cycloalkyl; Q is -C(O)-NR'R", wherein R' and R" are each independently selected from hydrogen, optionally substituted C 1-10 Alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, preferably each independently H, optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 Cycloalkyl or an optionally substituted 3-6 membered heterocyclic group.
16. The compound of claim 1, It is characterized in that The compound is selected from: 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[2,3-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)oxazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazolo[5,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)oxazolo[5,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[3,4-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluorothieno[3,2-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluorothieno[3,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluorofuro[3,2-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrrolo[3,2-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[5,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[5,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[3,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isothiazolo[4,3-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,5-dihydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,4-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[4,3-c]quinolin-4(5H)-one; 9-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[2,3-c]quinolin-4(5H)-one; 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thieno[3,2-c]quinolin-4(5H)-one; 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)thiazolo[4,5-c]quinolin-4(5H)-one; 9-fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[3,2-c]quinolin-4(5H)-one; 7-((4-(2-Fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[3,2-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylisoxazolo[4,5-c]quinolin-4(5H)-one; 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrrolo[1,2-c]quinazolin-5(6H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-chloro-pyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-Fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-chloro-pyrazolo[1,5-a]quinoxalin-4(5H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-methyl-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-methyl-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 7-((4-(2-Fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one; 7-((4-(2-Fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-furo[2,3-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-3,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one; 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-cyclopenta[c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2,3,5-tetrahydro-4H-cyclopenta[c]quinolin-4-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,2-c]quinolin-4(2H)-one; 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,2-c]quinolin-4(2H)-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,4-c]quinolin-4(1H)-one; 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3,5-dihydrofuro[3,4-c]quinolin-4(1H)-one; 7-((4-(6-methylcarbamoyl-2-methylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2-dihydrofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(6-methylcarbamoyl-2-fluoropyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1,2-dihydrofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluoro-2-methyl-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 6-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-1-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one; 6-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluorooxazolo[5,4-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorooxazolo[5,4-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-6-fluoroisoxazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-8-fluoroisoxazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,5-dihydro-4H-pyrrolo[2,3-c]quinolin-4-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-1-methyl-1,5-dihydro-4H-imidazo[4,5-c]quinolin-4-one; 7-((4-(2-(difluoromethyl)-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-fluorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylfuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-8-methylfuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chlorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-carbamoylpyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one; 6-fluoro-7-((4-(5-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 6-fluoro-7-((4-(6-(methylcarbamoyl)-2-(trifluoromethyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperidin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(5-methyl-1H-imidazol-2-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorofuro[3,4-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methylfuro[2,3-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,6-difluorofuro[2,3-c]quinolin-4(5H)-one; 7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one; 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-7-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-9-fluoropyrazolo[1,5-c]quinazolin-5(6H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperidin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(5-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-cyano-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(1H-imidazol-5-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-difluoromethyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-trifluoromethyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-6-fluoro-3-methyl-7-((3-((6-(methylcarbamoyl)pyridin-3-yl)amino)pyrrolidin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-6-fluoro-7-((3-((2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)amino)pyrrolidin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 8-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-10-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-10-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,7-difluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,7-difluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methyl-7-fluoroimidazo[1,2-c]quinazolin-5(6H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluorooxazolo[4,5-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,4-c]quinolin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)isoxazolo[3,4-c]quinolin-4(5H)-one; 7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoroimidazo[1,5-a]quinoxalin-4(5H)-one; (R)-7-((3-((6-(methylcarbamoyl)pyridin-3-yl)amino)pyrrolidin-1-yl)methyl)-6-fluorofuran[2,3-c]quinolin-4(5H)-one; 6-Fluoro-7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 6-fluoro-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[2,3-c]quinolin-4(5H)-one; 6-fluoro-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,4-c]quinolin-4(5H)-one; 6-fluoro-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)furo[3,2-c]quinolin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-2-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-3-methyl-7-((6-methylcarbamoyl-3',6'-dihydro-[3,4'-bipyridyl]-1'(2'H)-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-fluoro-3-methyl-7-((4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(2-fluoro-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(2-chloro-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-6-fluoro-7-((4-(2-fluoro-6-((tetrahydrofuran-3-yl)carbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-fluoro-3-methyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(6-(1H-imidazol-2-yl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-fluoro-7-((4-(2-fluoro-6-((methyl-d3)carbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-cyclopropyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(3-fluoro-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(2-methyl-4-(methylcarbamoyl)phenyl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-ethyl-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(2-fluoro-6-cyanopyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((2-fluoro-6-methylcarbamoyl-3',6'-dihydro-[3,4'-bipyridyl]-1'(2'H)-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)-3-methylpiperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-6-fluoro-3-methyl-7-((8-methylcarbamoyl-1,2,4a,5-tetrahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazin-3(4H)-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; 8-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 8-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 8-Fluoro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-chloro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-chloro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-chloro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 3,9-difluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-trifluoromethyl-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(ethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(cyclopropylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,8-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,8-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,8-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-((methyl-d3)carbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(2,2-difluoroethylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-cyano-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one (Example 188); 3-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 3-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 3-Fluoro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 3-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one; 3-Fluoro-7-((4-(2-methyl-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one; 3-Fluoro-7-((4-(2-chloro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-cyanopyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)-3-methylpiperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((2-fluoro-6-methylcarbamoyl-3',6'-dihydro-[3,4'-bipyridyl]-1'(2'H)-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; (R)-7-((8-methylcarbamoyl-1,2,4a,5-tetrahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazin-3(4H)-yl)methyl)-3,6-difluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2-methyl-3-chloropyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-fluoro-7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-2,3-dimethylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-cyano-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-6-fluoro-3-(trifluoromethyl)pyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-cyano-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3-isopropyl-6-fluoropyrazolo[1,5-a]quinoxalin-4(5H)-one; 6-Fluoro-7-(1-(4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)ethyl)-3-methylpyrazolo[1,5-a]quinoxalin-4(5H)-one; 7-Fluoro-8-((4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)imidazo[1,5-c]quinazolin-5(6H)-one; or a stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt thereof, or a mixture thereof, or a prodrug thereof.
17. Use of the compound according to any one of claims 1 to 16, or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof in the preparation of a medicament for treating or preventing a disease or condition responsive to inhibition of PARP activity; Preferably, the disease or disorder is cancer; preferably, the cancer is selected from liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphatic leukemia, chronic lymphatic leukemia, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, Wilms' tumor, cervical cancer, testicular cancer, soft tissue sarcoma, primary macroglobulinemia, bladder cancer, chronic myeloid leukemia, primary brain cancer, malignant melanoma, non-small cell lung cancer, small cell lung cancer, gastric cancer, cancer, colon cancer, malignant pancreatic insulinoma, malignant carcinoid cancer, choriocarcinoma, mycosis fungoides, head and neck cancer, osteogenic sarcoma, pancreatic cancer, acute myeloid leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary neoplasia, thyroid cancer, esophageal cancer, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial cancer, polycythemia vera, essential thrombocythemia, adrenocortical carcinoma, skin cancer, and prostate cancer; Preferably, the drug further comprises at least one known anticancer drug, or a pharmaceutically acceptable salt of the anticancer drug;Preferably, the anticancer drug is selected from one or more of the following groups: vorinostat, romidepsin, panobinostat, belinostat, palbociclib, busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, methylhydroxyellipticine, mingtopop, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxyuridine, fludarabine, nelarabine, cytarabine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, vinblastine, vincristine, long Primordialib, paclitaxel, ixabepilone, cabazitaxel, docetaxel, monoclonal antibody, panitumumab, necrotizumab, nivolumab, pembrolizumab, ramucirumab, bevacizumab, pertuzumab, trastuzumab, cetuximab, obinutuzumab, ofatumumab, rituximab, alemtuzumab, ibritumomab tiuxetan, tositumomab, brentuximab, daratumumab, elotuzumab, ofatumumab, dinutuximab, blinatumomab, ipilimumab, Avastin, Herceptin, rituximab, trastuzumab-emtansine conjugate T-DM1, humanized anti-HER2 antibody-drug conjugate trastuzumab Deruxtecan, Trastuzumab Emtansine, Humanized anti-TROP2 monoclonal antibody-drug conjugate Datopotamab Deruxtecan, Gemtuzumab Ozogamicin, CD30-directed antibody-drug conjugate Brentuximab Vedotin, Inotuzumab Ozogamicin, Sacituzumab govitecan, Enfortumab Vedotin, Belantamab Mafodotin, imatinib, gefitinib, erlotinib, osimertinib, afatinib, ceritinib, alectinib, crizotinib, erlotinib, lapatinib, sorafenib, regorafenib, vemurafenib, dabrafenib, aflibercept, sunitinib, nilotinib, dasatinib, bosutinib, pralsetinib, ibrutinib, cabozantinib, lenvatinib, vandetanib, trametinib, cobimetinib, axitinib, temsirolimus, Idel alisib, pazopanib, tebuconazole, everolimus, tamoxifen, letrozole, fulvestrant, mitoguanidine, octreotide, retinoic acid, arsenic, zoledronic acid, bortezomib, carfilzomib, ixazomib, vismodegib, sonidegi, denosumab, thalidomide, lenalidomide, venetoclax, aldesleukin (recombinant human interleukin-2), and sipueucel-T (a prostate cancer vaccine); Preferably, the medicament is used in combination with radiation therapy.
18. A pharmaceutical composition comprising the compound according to any one of claims 1 to 16, or its stereoisomer, tautomer, N-oxide, hydrate, solvate, isotope-labeled compound or pharmaceutically acceptable salt, or a mixture thereof, or a prodrug thereof and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition according to claim 18, It is characterized in that The pharmaceutical composition further contains at least one known anticancer drug, or a pharmaceutically acceptable salt of the anticancer drug; preferably,The at least one known anticancer drug is selected from the group consisting of vorinostat, romidepsin, panobinostat, belinostat, palbociclib, busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, methylhydroxyellipticine, mingtopop, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxyuridine, fludarabine, nelarabine, cytarabine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, vinblastine, vincristine, vinorelbine brine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, monoclonal antibody, panitumumab, necrotizumab, nivolumab, pembrolizumab, ramucirumab, bevacizumab, pertuzumab, trastuzumab, cetuximab, obinutuzumab, ofatumumab, rituximab, alemtuzumab, ibritumomab tiuxetan, tositumomab, brentuximab, daratumumab, elotuzumab, ofatumumab, dinutuximab, blinatumomab, ipilimumab, avastin, herceptin, rituximab, trastuzumab-emtansine conjugate T-DM1, humanized anti-HER2 antibody-drug conjugate trastuzumab Deruxtecan, Trastuzumab Emtansine, Humanized anti-TROP2 monoclonal antibody-drug conjugate DatopotamabDeruxtecan, Gemtuzumab Ozogamicin, CD30-directed antibody-drug conjugate Brentuximab Vedotin, Inotuzumab Ozogamicin, Sacituzumab govitecan, Enfortumab Vedotin, Belantamab Mafodotin, Imatinib, Gefitinib, Erlotinib, Osimertinib, Afatinib, Ceritinib, Alectinib, Crizotinib, Erlotinib, Lapatinib, Sorafenib, Regorafenib, Vemurafenib, Dabrafenib, Aflibercept, Sunitinib, Nilotinib, Dasatinib, Bosutinib, Pratinib, Ibrutinib, Cabozantinib, Lenvatinib, Vandetanib, Trametinib, Cobimetinib, Axitinib, Temsirolimus, Idela lisib, pazopanib, terbutaline, everolimus, vorinostat, romidepsin, panobinostat, belinostat, tamoxifen, letrozole, fulvestrant, mitoguanidine, octreotide, retinoic acid, arsenic, zoledronic acid, bortezomib, carfilzomib, ixazomib, vismodegib, sonidegi, denosumab, thalidomide, lenalidomide, venetoclax, Aldesleukin (recombinant human interleukin-2) and Sipueucel-T (prostate cancer treatment vaccine).
